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Abstract 
HIV-associated neurocognitive impairment (HIV NCI) persists in persons living with HIV (PLWH) despite 
the availability of suppressive combination antiretroviral therapy. Chronic inflammation, oxidative stress, 
and blood-brain barrier (BBB) disruption are well-known in HIV infection and likely contribute to the 
development of HIV NCI. Post-mortem and neuroimaging studies in PLWH demonstrate region-specific 
neuroinflammation, injury, and BBB damage within the brain, indicating that the processes causing HIV 
NCI might therefore be region-specific. We previously identified the highly inducible antioxidant enzyme 
heme oxygenase-1 (HO-1) as a potential mediator of HIV neuropathogenesis, showing that HO-1 
expression in the prefrontal cortex is reduced in PLWH with HIV NCI compared to both HIV-negative 
individuals and PLWH without HIV NCI, and this reduction associates with increased CSF HIV RNA, type I 
interferon-stimulated gene expression, and immunoproteasome expression. HO-1 is expressed 
throughout the brain, and its expression in brain microvascular endothelial cells has been shown to 
support BBB functions. This thesis expounds our understanding of the role for HO-1 in HIV 
neuropathogenesis through two approaches: i) Regional ex vivo analysis of autopsied brains of PLWH 
without HIV NCI; and ii) manipulation of HO-1 expression in in vitro models of the BBB using human brain 
microvascular endothelial cells. We show that PLWH without HIV NCI have stable or increased HO-1 
expression compared to HIV-negative individuals that associates positively with CSF and plasma HIV 
RNA consistently throughout the brain. HO-1 expression also associates positively with type I interferon-
stimulated gene, immunoproteasome subunit, and endothelial adhesion marker expression. We also 
noted distinct patterns of neuroinflammation in certain brain regions (posterior cingulate cortex, 
cerebellum, and globus pallidus). Finally, we demonstrate manipulation of HO-1 expression in a human 
endothelial cell line and primary human brain microvascular endothelial cells, outlining experimental 
parameters for future experiments to determine the role for endothelial HO-1 in BBB functioning during 
HIV infection. Our work suggests that in PLWH without HIV NCI, HO-1 is driven by HIV replication as a 
component of an inflammatory response throughout the brain, including within the BBB, and that the role 
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HIV-associated neurocognitive impairment (HIV NCI) persists in persons living with HIV (PLWH) 
despite the availability of suppressive combination antiretroviral therapy. Chronic inflammation, 
oxidative stress, and blood-brain barrier (BBB) disruption are well-known in HIV infection and likely 
contribute to the development of HIV NCI. Post-mortem and neuroimaging studies in PLWH 
demonstrate region-specific neuroinflammation, injury, and BBB damage within the brain, 
indicating that the processes causing HIV NCI might therefore be region-specific. We previously 
identified the highly inducible antioxidant enzyme heme oxygenase-1 (HO-1) as a potential 
mediator of HIV neuropathogenesis, showing that HO-1 expression in the prefrontal cortex is 
reduced in PLWH with HIV NCI compared to both HIV-negative individuals and PLWH without HIV 
NCI, and this reduction associates with increased CSF HIV RNA, type I interferon-stimulated gene 
expression, and immunoproteasome expression. HO-1 is expressed throughout the brain, and its 
expression in brain microvascular endothelial cells has been shown to support BBB functions. This 
thesis expounds our understanding of the role for HO-1 in HIV neuropathogenesis through two 
approaches: i) Regional ex vivo analysis of autopsied brains of PLWH without HIV NCI; and ii) 
manipulation of HO-1 expression in in vitro models of the BBB using human brain microvascular 
endothelial cells. We show that PLWH without HIV NCI have stable or increased HO-1 expression 
compared to HIV-negative individuals that associates positively with CSF and plasma HIV RNA 
consistently throughout the brain. HO-1 expression also associates positively with type I interferon-
stimulated gene, immunoproteasome subunit, and endothelial adhesion marker expression. We 
also noted distinct patterns of neuroinflammation in certain brain regions (posterior cingulate cortex, 
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cerebellum, and globus pallidus). Finally, we demonstrate manipulation of HO-1 expression in a 
human endothelial cell line and primary human brain microvascular endothelial cells, outlining 
experimental parameters for future experiments to determine the role for endothelial HO-1 in BBB 
functioning during HIV infection. Our work suggests that in PLWH without HIV NCI, HO-1 is driven 
by HIV replication as a component of an inflammatory response throughout the brain, including 
within the BBB, and that the role for HO-1 within this process can be modeled using primary human 
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CHAPTER 1: Introduction  
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1.1 HIV-associated neurocognitive impairment in the era of combination 
antiretroviral therapy  
The World Health Organization estimates that 75 million people have been infected and 32 million 
people have died of HIV/AIDS since the outset of the pandemic in the 1980s. With access and 
adherence to combination antiretroviral therapy (cART) regimens, persons living with HIV (PLWH) 
have a good prognosis and life expectancy nearly on par with the general population (1). However, 
various barriers to treatment prevent many PLWH from achieving viral suppression, and the 
pandemic persists: at the end of 2018, almost 38 million people worldwide were living with HIV and 
there were 1.7 million new infections (WHO). To combat this continuing global public health 
challenge, in 2014 the United Nations Program on HIV and AIDS published the 90-90-90 treatment 
target: 90% of PLWH knowing their HIV status, 90% of diagnosed PLWH receiving cART, and 90% 
of those on cART achieving viral suppression by 2020 (2). A report synthesizing data from 60 
countries showed that through 2018, 79% of PLWH worldwide knew their HIV status; 78% of those 
individuals were receiving cART, and 86% of those individuals were virally suppressed (3). The 
global percentages of PLWH who know their status and are receiving cART has significantly 
improved since 2015, but the percentage of cART-treated PLWH who have achieved viral 
suppression has remained stable (3). While many countries will not reach the 90-90-90 target in 
2020, the advances in model-based approaches to national estimates will be beneficial for years 
to come (3). Furthermore, the global 90-90-90 framework will continue to identify which populations 
and countries require additional investment to reach testing and treatment goals. Though reaching 
the UNAIDS 90-90-90 target will certainly limit the human and economic costs of HIV/AIDS, tens 
of millions of individuals will be living with HIV on cART long-term, as cure strategies that would 
allow interruption or cessation of cART remain out of reach.  
 
Persons living with chronic HIV have increased risk for many comorbid conditions, including 
cardiovascular disease, non-AIDS-related cancers, diabetes mellitus, hepatic and renal disease, 
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and metabolic disorders, many of which will increase in prevalence as the population of PLWH 
ages (4). HIV infection is also associated with a number of neurologic complications, including 
meningitis, acute inflammatory polyneuropathy, immune reconstitution inflammatory syndrome, 
chronic inflammatory polyneuropathy, distal symmetric polyneuropathy, progressive multifocal 
leukoencephalopathy, HIV encephalitis (HIVE), and a spectrum of neurocognitive impairment 
collectively termed HIV-associated neurocognitive disorders (HAND) (5). Similar to systemic 
outcomes, neurologic outcomes with HIV infection have improved dramatically with cART. In the 
pre-cART era, 20% of PLWH died with HIVE, histopathologically defined by astrogliosis and HIV 
p24-positive multinucleated giant cells (6-8). HIVE rarely, if ever, occurs in PLWH on suppressive 
cART, but some form of HAND persists in up to 50% of PLWH (9). Importantly, HAND is exclusively 
clinically diagnosed. In contrast to HIVE, which has a clearly delineated neuropathologic signature, 
HAND does not have any definitive associated pathology (10). 
 
HAND is diagnosed through a battery of neuropsychological tests spanning at least five of the 
seven following neurocognitive domains: verbal/language; attention/working memory; 
abstraction/executive function; memory (learning; recall); speed of information processing; 
sensory-perceptual; motor skills (11). The criteria for HAND diagnosis are as follows: Performance 
one standard deviation below the mean for demographically adjusted normative scores in two or 
more domains, wherein neurocognitive impairment cannot be attributed to a comorbid condition, 
qualifies as asymptomatic neurocognitive impairment (ANI). Individuals who meet the criteria for 
ANI and also have impairment in activities of daily living (ADLs) are diagnosed with mild 
neurocognitive disorder (MND). Finally, individuals who perform two standard deviations below the 
mean for demographically adjusted normative scores in at least two cognitive domains and have 
impairment in ADLs are diagnosed with HIV-associated dementia, or HAD. Presently, the majority 
of individuals diagnosed with HAND fall within the ANI category. Still, 10-15% of PLWH experience 
functional neurocognitive impairment in the form of either MND or HAD, and diagnosis of ANI 
4 
 
increases risk for future diagnosis of MND or HAD by two- to six-fold (9, 12). Emerging data 
emphasize the significance of differentiating between ANI more severe HAND subtypes MND and 
HAD when studying HIV-associated neurocognitive impairment (HIV NCI), as ANI criteria can 
positively diagnose more than 30% of a normative reference population (13).  
 
There are no definitive diagnostic or prognostic biomarkers for HIV NCI, and the understanding of 
its cause is incomplete. Among the potential biomarkers of CNS injury in HIV, neurofilament light 
chain (NFL), a major structural component of axons, has perhaps shown the most promise. CSF 
NFL is elevated in PLWH with both severe and mild HIV NCI (14, 15). CSF NFL is transiently 
elevated during primary HIV infection, and increased CSF NFL associates negatively with blood 
CD4 T-cell count in neuroasymptomatic PLWH, demonstrating its sensitivity to fluctuating neuronal 
injury throughout the course of HIV infection (15). NFL levels within CSF and plasma are strongly 
associated, suggesting that plasma NFL can be used as a surrogate marker for CSF NFL (16). 
This eliminates the necessity for invasive lumbar puncture procedures when measuring NFL as a 
biomarker (16). Plasma NFL associates negatively with neuropsychological test performance, but 
it has not been fully vetted in the cART-treated population (16, 17).  
 
In terms of the cause of HIV NCI, neurological symptoms associate with HIV RNA in cerebrospinal 
fluid (CSF) during primary infection, but in the context of viral suppression with cART, ongoing 
active viral replication is not a feasible cause of HIV NCI (18). There are several known risk factors 
to HIV NCI including CD4 nadir, duration of HIV disease, age, co-infections, diabetes mellitus, 
substance abuse, and poor adherence to antiretroviral therapy (9, 19), and several alternative 
drivers of HIV NCI in cART-treated PLWH have been proposed. One is the ‘legacy effect’ of 
irreversible neuronal damage incurred during the initial HIV infection within the CNS prior to 
treatment, that translates to development of HIV NCI during chronic infection (20). Next is chronic 
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low-level inflammation and oxidative stress within the CNS, which persists even in cART-treated 
PLWH (discussed below) (21). Finally, direct neurotoxicity of CNS-penetrating antiretroviral drugs 
has been supported by various in vitro studies, though relevance of these mechanisms in vivo is 
controversial (22). Despite these advances, there remains a great incentive to fully elucidate the 
mechanistic drivers of HIV NCI and develop adjunctive therapies to cART that will further improve 
quality of life for PLWH. 
 
1.2 Inflammation and oxidative stress at the blood-brain barrier in HIV infection 
Among the potential drivers of HIV NCI is the state of persistent inflammation, immune activation, 
and oxidative stress systemically and within the CNS experienced by PLWH (21, 23). HIV RNA is 
detectable in CSF and brain parenchyma within weeks of infection (24-28). The most likely 
mechanism of HIV entry into the CNS is trafficking of infected CD4+ lymphocytes or monocytes 
across the blood-brain barrier (BBB) by transendothelial migration, although permeation of cell-free 
virus is plausible (27, 29-31). The cellular makeup of the BBB consists of highly specialized brain 
microvascular endothelial cells (BMECs), supported by smooth muscle-like pericytes embedded 
within the basement membrane, and astrocyte endfeet that secrete supportive and regulatory 
factors (32, 33). These cells work in concert to protect the brain from the circulation and tightly 
regulate which molecules and cells are permitted to enter and leave the CNS. The BBB is unique 
among vascular endothelial barriers due to the selectivity of its tight junctions, high transendothelial 
electrical resistance, and tight regulation of transendothelial cellular migration (33, 34). 
 
Once in the CNS, HIV infects resident perivascular macrophages and microglia, which comprise 
the HIV reservoir within the CNS (35). Productively infected macrophages secrete neurotoxic 
factors including viral proteins and glutamate, as well as pro-inflammatory cytokines (9, 36). 
Concurrently, depletion of CD4+ lymphocytes in the gut-associated lymphoid tissue during acute 
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HIV infection contributes to compromise of the gut epithelial barrier, resulting in microbial 
translocation (37). Subsequent immune activation of circulating monocytes is evidenced by 
increased soluble CD14, sCD163, and monocyte-associated CD14 and CD16 in plasma (38-41). 
The BBB is inevitably exposed to microbial translocation products in the circulation, including 
bacterial nucleic acids and lipopolysaccharide (LPS), which disrupts tight junction integrity and 
promotes trafficking of immune cells into the CNS (39, 42). In HIV, this equates to exacerbation of 
infected and/or activated immune cell transmigration and increased permeability of the BBB to cell-
free virus and other harmful factors in the circulation (43). Thus, during primary HIV infection (Fiebig 
stages I-II), the brain is challenged by i) active viral replication and release of neurotoxic viral 
proteins; ii) compromise of its protective barrier; and iii) influx of pro-inflammatory cytokines and 
oxidative stress as a result of the aforementioned processes (44).  
 
BBB disruption during HIV infection often involves inflammation oxidative stress, and associates 
with HIV NCI in many studies (45-48). Perivascular inflammation independent of productive HIV 
infection has been observed in acute, asymptomatic HIV infection (45). Upregulated endothelial 
transcripts accompany HIV NCI without demonstrable neuropathological changes (46). The HIV 
DNA reservoir is associated with CSF immune activation, gliosis, neuronal damage, and cognitive 
impairment in treatment-naïve individuals (23). Boven et al. demonstrated immunohistochemical 
staining for nitrotyrosine in perivascular areas (indicating free radical nitric oxide production) in HIV 
NCI patients that was accompanied by damaged blood vessels and abnormal staining of tight 
junction protein ZO-1, indicating oxidative stress associating with a leaky barrier (47, 48). PLWH 
have decreased glutathione levels both in the CNS and systemically, which associates with 




Introduction of effective cART eliminates productive viral replication, fundamentally changing the 
immune challenge to the CNS. Nonetheless, inflammation, oxidative stress, and BBB disruption 
persist within the CNS in treated PLWH.  Elevated CSF/plasma albumin ratio, indicative of 
increased BBB permeability, associates with CSF HIV RNA and immune activation marker 
neopterin in untreated PLWH; in CSF-controlled patients, CSF/plasma albumin ratio instead 
associates with neuronal damage and astrocytosis (52, 53). One longitudinal study indicated that 
while neopterin decreased over time with treatment, most PLWH still had elevated neopterin in 
CSF after more than three years of viral suppression (CSF HIV RNA <50 copies/ml) (54). Persistent 
neuroinflammation at the BBB in treated PLWH is also indicated by metabolic signatures and post-
contrast enhancement in magnetic resonance spectroscopy (MRS) that associate with HIV NCI in 
some cases (55-58). Finally, while antiretroviral therapy decreases levels of soluble endothelial 
activation markers (ICAM-1, VCAM-1, von Willebrand factor) in plasma of PLWH, they remain 
elevated in comparison to HIV-negative individuals (59). 
 
The mechanisms by which blood-brain barrier damage, persistent oxidative stress, and 
inflammation contribute to HIV NCI are not entirely clear. It may be important to consider not just 
damage to the endothelial blood-brain barrier, but to the neurovascular unit (NVU), which describes 
the entire CNS blood vessel compartment and extends, critically, to include perivascular neuronal 
processes and synapses. In total, the NVU includes astrocytic endfeet, neuronal processes and 
synapses, microvascular endothelial cells, pericytes, pervascular macrophages and microglia, 
CNS extracellular spaces, subarachnoid spaces and CSF, and blood plasma (10). Evidence of 
direct innervation of microvascular endothelial cells and/or astrocytic endfeet suggests bidirectional 
communication between neurons and the CNS vasculature that regulates blood flow and BBB 
permeability (32). GABAergic transmission specifically is known to control microvascular blood flow 
through regulation of pericyte contractility (60, 61), and is abnormally low in neocortex of PLWH, 
suggesting a mechanism by which NVU dysregulation impacts BBB function (46). Abnormal 
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cerebral blood flow is observed in PLWH with and without HIV NCI, which may indicate early 
neurovascular injury (62). A supportive role for astrocytes within the NVU has long been suggested, 
as injection of astrocytes induced BBB properties in non-neural endothelial cells in the rat eye in 
vivo, and co-culture of astrocytes with brain microvascular endothelial cells enhances BBB 
characteristics in vitro (63-65). Astrocytic secretion of soluble factors, notably Sonic Hedgehog, 
directly support BBB properties of microvascular endothelial cells in vitro and in vivo (66). Exposure 
of astrocytes in an in vitro BBB model to HIV disrupts BBB functions through endothelial apoptosis 
and altered astrocyte endfeet signaling (67). This is recapitulated in brain tissue of SIV-infected 
macaques, where apoptotic endothelia cells are observed in contact with astrocytes containing 
SIV-p41 antigen (67). Recent work has emphasized the relevance of “vascular cognitive 
impairment” to our evolving understanding of HIV NCI, with the NVU as the proposed common 
mechanistic target of these conditions, and a worthy target for neurotherapeutics in PLWH (68).  
 
1.3 Antioxidant response enzyme heme oxygenase-1 in HIV neuropathogenesis 
Because of the persistence of inflammation and oxidative stress in the CNS in PLWH and their 
association with HIV NCI, our group has investigated of the role for the host antioxidant response 
in HIV neuropathogenesis. The endogenous host antioxidant response consists of cytoprotective 
and detoxifying effector proteins whose genes have a common regulatory element within their 
promoter regions termed the antioxidant response element (ARE), which is regulated by the Kelch-
like ECH associated protein (Keap1)/nuclear factor erythroid 2-related factor (Nrf2) pathway (69-
71). Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1, which forms a 
homodimer and binds to actin and Nrf2 (Fig. 1.1). In this conformation, Nrf2 is targeted for 
ubiquitination and proteomic degradation. Keap1 contains several reactive cysteine residues that 
allow it to act as a chemical sensor (72). In response to changes in cellular redox state due to 
reactive oxygen species, electrophilic species, or reduced antioxidant capacity, conformational 
change in Keap1 results in release of Nrf2 (71). Nrf2 then translocates to the nucleus and binds 
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AREs, inducing transcription of target genes (72, 73). Nrf2 target gene products have diverse 
effector functions that provide multifaceted protection to the cell including direct antioxidant activity, 
xenobiotic transport, glutathione synthesis and regeneration, synthesis of reducing species, 
inhibition of inflammation, and repair and removal of damaged proteins (72). 
	
Figure 1.1 The Nrf2-Keap1-ARE Pathway 
Illustration of Nrf2-Keap-1 interactions leading to induction of antioxidant response element-containing 
genes, specifically HO-1. Adapted from (72) and (74) 
 
Within our studies of the host antioxidant response in HIV infection, we have identified antioxidant 
enzyme heme oxygenase (HO) as an important factor in the development of HIV NCI. HO executes 
the rate limiting step of heme catabolism, oxygenating heme to ferrous iron, biliverdin, and carbon 
monoxide (CO). Ferrous iron is sequestered by ferritin, and biliverdin is transformed to bilirubin by 
biliverdin reductase (Fig. 1.1). HO exists in two isoforms, heme oxygenase-1 (HO-1) and heme 






Figure 1.2 Heme catabolism 
Schematic depicting catabolism of heme by HO. Oxygenation of heme by HO yields carbon monoxide, iron, 
and biliverdin. Iron is bound by ferritin and biliverdin reductase converts biliverdin to bilirubin. 
	
HO-1 transcription is primarily regulated as a part of the Nrf2-antioxidant response element (ARE) 
signaling pathway (71), but several other transcription factors can bind the HO-1 promoter and 
regulate its transcription: activator protein-1 and -2 (AP-1, AP-2), nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB), hypoxia-inducible factor-1 (HIF-1), signal transducer and 
activator of transcription 3 (STAT3), and broad complex-tramtrack-bric-a-brac-domain and 
cap’n’collar homology 1 (BACH1) (Fig. 1.2) (76-81). Critically, BACH1 binds the same antioxidant 
response element as Nrf2 within the HO-1 promoter, preventing Nrf2 from binding and thus 
suppressing HO-1 transcription (Fig. 1.1). BACH1 dissociates from the HO-1 promoter with 
exposure to heme and oxidative stress, allowing Nrf2 to bind and activate HO-1 transcription (82, 






Figure 1.3 The heme oxygenase-1 promoter 
Illustration of the heme oxygenase-1 promoter. Putative Nrf2, AP-1, AP-2, NFκB HIF-1 STAT-3, and BACH1 
binding sites are indicated. Loci of (GT)n microsatellite dinucleotide repeat polymorphism and single 
nucleotide polymorphisms A(-413)T (rs2071746) and G(-1135)A (rs2071747) are also represented. The arrow 
indicates the transcription initiation site, and distance from this site is shown in kilobase pairs. Adapted from 
(76). 
	
In addition to the described transcription factor binding sites, the HO-1 promoter contains a few 
polymorphisms (Fig. 1.2): a (GT)n microsatellite dinucleotide repeat polymorphism and two single 
nucleotide polymorphisms (SNPs), A(-413)T (rs2071746) and G(-1135)A (rs2071747) (85-87). The 
T(-413)A SNP and the (GT)n dinucleotide repeat polymorphism have each been shown to affect 
HO-1 transcription. In a luciferase assay testing the activity of promoters with each allele of the T(-
413)A SNP in bovine aortic endothelial cells, the ‘A’ allele promoter had higher activity. The ‘AA’ 
genotype for this SNP associates with reduced risk for ischemic heart disease, suggesting a 
protective effect of higher HO-1 promoter activity (86). The (GT)n dinucleotide repeat polymorphism 
similarly impacts transcription in that ‘short’ repeat length alleles are associated with increased 
basal transcriptional activity and inducibility of HO-1 expression using luciferase reporter assays 
(88, 89). Lymphoblastoid cell lines derived from individuals with either ‘short/short’ repeat length 
alleles demonstrated significantly higher HO-1 mRNA expression and enzymatic activity in 
response to oxidative stress compared to those with ‘long/long’ repeat length alleles, and 
furthermore ‘short/short’ cell lines were more resistant to apoptosis induced by oxidative stress 
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(90). These observations have also been recapitulated in human umbilical vein endothelial cells 
(91). 
 
Given the numerous factors governing HO-1 transcription, its expression is thus induced in 
response to not only heme levels but many other cellular stressors including cytokines and reactive 
oxygen species that are relevant to HIV infection (92). In contrast, HO-2 is not regulated through 
the ARE pathway and is considered to be constitutively expressed, although its expression levels 
can change in response to a few factors (93-95). In the brain, HO-2 is expressed in neuronal and 
glial cells and is the predominant isoform. HO-1 is expressed in glial cells and not in neurons, which 
demonstrate little to no HO-1 expression even in response to cellular stressors	(96, 97).  
 
The antioxidative and anti-inflammatory effects of HO-1 are multifactorial, through regulation of 
intracellular heme levels and the properties of its metabolites. Heme has many important biological 
roles as a prosthetic moiety on hemoproteins, e.g. hemoglobin, myoglobin, and cytochromes. 
However, free heme is a potent pro-oxidant and its lipophilic properties allow it to intercalate into 
and disrupt the cell membrane (98, 99). The byproducts of heme catabolism, i.e. carbon monoxide 
and bilirubin each exert their own antioxidative and anti-inflammatory effects. Carbon monoxide 
generated by HO-1 enzymatic activity suppresses endothelial apoptosis (100). Carbon monoxide 
also affects cytokine secretion, inhibiting TNFa and IL-1b via the p38 MAPK pathway, and 
increasing expression of anti-inflammatory cytokine IL-10 (101). Bilirubin scavenges reactive 
oxygen species and inhibits TNFa-induced adhesion molecule expression (102, 103). Bilirubin can 
also modulate innate immunity by interfering with the complement system and regulating Fc 
receptor and MHC class II expression (98). 
In recent years, our group has defined a novel role for HO-1 in HIV neuropathogenesis and 
identified it as a potential therapeutic target for HIV NCI. In a study of autopsied brains of PLWH 
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and HIV-negative individuals from the National NeuroAIDS Tissue Consortium (NNTC), we 
observed that PLWH with HIV NCI and/or HIV encephalitis had reduced prefrontal cortex HO-1 
expression compared to both neurocognitively normal PLWH and HIV-negative individuals. Lower 
HO-1 protein in prefrontal cortex associated with higher parenchymal and CSF HIV load, type I 
interferon-stimulated gene expression, and macrophage activation (36). In vitro studies showed 
that HIV infection of monocyte-derived macrophages (MDM) leads to reduced expression of HO-1 
RNA and protein in a replication-dependent manner. Deficient HO-1 in HIV-infected MDM 
associated with release of neurotoxic levels of glutamate into the supernatant, and this was rescued 
with pharmacologic induction of HO-1 in HIV-infected MDM (36). These studies identified deficient 
HO-1 expression in brains of PLWH that associates with HIV NCI and encephalitis and furthermore 
linked HO-1 deficiency in HIV-infected MDM to glutamate-mediated neurotoxicity, suggesting a 
mechanism by which HO-1 deficiency in vivo might yield neuronal death and NCI. 
 
Interestingly, further study within this cohort showed that PLWH with HIV NCI and/or encephalitis 
had increased HO-1 RNA compared to neurocognitively normal PLWH and HIV-negative 
individuals, and that HO-1 RNA and protein were negatively associated (104). This discordance 
was not consistent with the RNA and protein HO-1 deficiency observed in vitro in HIV-infected MDM 
(36). Alternatively, in vitro studies using human fetal astrocytes chronically exposed to IFNg 
demonstrated post-translational degradation of HO-1 by the immunoproteasome (Fig. 4) (104). 
Others have demonstrated that PLWH have increased immunoproteasome subunit expression in 
prefrontal cortex that associates with HIV loads, HIV NCI and HIV-encephalitis (105).  Indeed, 
increased immunoproteasome subunit expression in prefrontal cortex of PLWH with HIV 
encephalitis associated negatively with HO-1 protein (104). As IFNg is an HIV-associated immune 





Figure 1.4 Immunoproteasome-mediated HO-1 degradation 
Illustration of HO-1 degradation by the immunoproteasome in human fetal astrocytes. Chronic exposure (15 
days) to IFNg leads to replacement of constitutive proteasome subunits with immunoproteasome 
subunits. The immunoproteasome enhances post-translational HO-1 degradation and decreases 
its half-life. Adapted from CE Kovacsics (104). 
 
We also addressed the potential role for the previously mentioned (GT)n dinucleotide repeat 
polymorphism in the HO-1 promoter region in HIV NCI. Along with increased promoter activity, 
shorter repeat length alleles of this polymorphism associate with better outcomes in numerous 
diseases that have inflammation and oxidative stress as critical elements to their pathogeneses 
(106). Examples of disease states in which shorter repeat length alleles are protective include 
ischemic stroke, ischemic heart disease, hypertension, coronary heart disease, coronary artery 
disease in diabetic patients, necrotizing acute pancreatitis, rheumatoid arthritis, sepsis, pneumonia, 
and emphysema (86-89, 107-112). Seu et al. demonstrated that longer (GT)n repeat length alleles 
associated with higher monocyte activation and viral loads in African-American PLWH, suggesting 
that this polymorphism can modulate systemic HIV disease outcomes (113). We found significant 
associations between this polymorphism and risk for HIV-encephalitis, as well as type I interferon-
stimulated gene expression and T-lymphocyte activation within the prefrontal cortex of PLWH 
(114). In a separate clinical cohort study of PLWH, we observed modulating effects of the HO-1 
(GT)n promoter dinucleotide repeat on risk for HIV NCI (115).  These observations suggest a 
balance between transcriptional and post-translational mechanisms of HO-1 modulation that 
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determine parenchymal HO-1 levels in the setting of neuroinflammation in prefrontal cortex, and 
they also suggest a role for HO-1 expression in modulating risk for HIV NCI. 
 
Our previous work has established that HO-1 modulates risk for HIV NCI and HIV encephalitis and 
has identified mechanisms by which HIV replication or HIV-associated chronic inflammation reduce 
HO-1 expression in macrophages and astrocytes, respectively. HO-1 has also been shown to 
support BMEC function in various models by limiting oxidative stress and inflammation. 
Administration of curcumin and resultant induction of HO-1 in a model of oxygen glucose 
deprivation reduced barrier permeability through restoration of tight junction protein expression 
(116). Pharmacologic upregulation of HO-1 by cobalt protoporphyrin (CoPP), a potent inducer of 
HO-1 through destabilization of BACH1 and stabilization of Nrf2 (117), ameliorated glutamate-
mediated oxidative stress and apoptosis in murine BMECs (118). These data suggest that deficient 
HO-1 at the BBB might contribute to its dysfunction, and equally that therapeutic induction of HO-
1 at the BBB could support its function in HIV infection.   
 
1.4 Region-specific brain vulnerability to HIV infection: implications for HIV NCI 
As previously mentioned, HIV NCI does not have a defined neuropathology. Still, researchers have 
long sought to characterize histopathologic, neuroimaging, and CSF biomarker abnormalities in 
PLWH, with the hope of identifying key diagnostic or prognostic correlates of HIV NCI. While this 
goal has not yet been met, these studies have shed light on region-specific effects of HIV infection 
on the brain in treated and untreated PLWH, identifying distinct cortical and sub-cortical 
abnormalities and their relevance to HIV NCI. With the implementation of cART, not only has the 
severity of HIV NCI decreased, but the clinical presentation of HIV NCI has also shifted. Pre-cART, 
individuals with HIV NCI commonly presented with motor dysfunction and memory deficits pointing 
to sub-cortical involvement, and without treatment, HIV NCI would commonly progress to severe 
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dementia (119, 120). In PLWH on cART, however, HIV NCI typically presents with deficits to 
executive functioning and working memory, suggesting involvement of the prefrontal cortex (121). 
HIV NCI is not typically progressive in PLWH on cART; in one longitudinal study of PLWH, 77% of 
those individuals were neurocognitively stable, while 13% declined and 10% improved over the 
course of 4 years (122). Thus, evolution of clinical presentation of HIV NCI with cART suggests 
potential change for its etiology, with regards to both the particular regions damaged and the source 
of that damage. 
 
Studies to identify regional distribution of HIV RNA and capsid protein (p24 antigen) have shown 
higher levels of HIV in the basal ganglia (dorsal striatum [caudate + putamen], ventral striatum 
[olfactory tubercle + nucleus accumbens], globus pallidus, subthalamic nucleus, substantia nigra) 
compared to neocortex (123-125). Perhaps because they harbor comparatively more virus, the 
basal ganglia are exceptionally vulnerable to BBB damage and atrophy in untreated PLWH. Indeed, 
higher CSF HIV RNA associates with atrophy of the caudate in individuals with HIV NCI (126). In 
MRI studies, smaller basal ganglia volume differentiates PLWH with dementia or encephalitis from 
those without (127, 128), and lower caudate volume specifically associates with worse performance 
on neuropsychological tests and/or dementia (129-131). Furthermore, progressive volume loss in 
the caudate has been linked to disease stage and rate of CD4 count decline (132). Vulnerability of 
the basal ganglia is suggested even in treated PLWH in some studies; Chaganti et al. described 
BBB disruption measured by contrast enhanced perfusion MRA in basal ganglia that associates 
with CSF neopterin and CSF/serum albumin ratio in virally suppressed PLWH (56). Smaller 
volumes in the basal ganglia associate with executive function deficits in PLWH on cART, indicating 
relevance of the basal ganglia to HIV NCI even in treated individuals (133). More pronounced 
atrophy of sub-cortical regions including the basal ganglia has been observed in older PLWH, 





Because of the prevalence of executive function deficits in HIV NCI, the prefrontal cortex has also 
been of particular interest to the neuroHIV field. PLWH have cortical thinning in prefrontal cortex, 
among other cortical areas, that associates with HIV NCI (136). In women living with HIV, stress 
can exacerbate prefrontal cortical volume loss that associates with learning and memory deficits 
(137). Using blood oxygen level dependent functional MRI (fMRI) to measure real-time changes in 
brain metabolism, Ann et al. showed that resting-state functional connectivity between the 
prefrontal cortex and precuneus also decreased in PLWH with HIV NCI (138), and multiple studies 
have identified impaired frontostriatal circuitry in PLWH. In treatment-naïve PLWH, prefrontal 
cortical thinning associates with impaired striatal functioning (139). Another fMRI study 
demonstrated impaired functional connectivity between the prefrontal cortex and basal ganglia 
regions in PLWH with mild NCI (140). Ipser et al. made similar observations of reduced connectivity 
between prefrontal cortex and caudate in PLWH on cART that associated with NCI, and particularly 
in younger participants (141). Together, these data point to the prefrontal cortex and basal 
ganglia/striatum as key regions for pathogenesis of HIV NCI. Indeed, our previous studies showed 
reduced HO-1 protein in the prefrontal cortex and striatum (caudate), but not occipital cortex or 
cerebellum of PLWH with HIV NCI and HIV-encephalitis, suggesting that a deficient HO-1 response 
in those regions might contribute to dysfunction (36).  
 
Still, the potential for significance of dysfunction in other regions remains, especially in the post-
cART era when brain structural changes in HIV NCI are less pronounced and less consistent (142). 
Besides prefrontal cortex, which has been studied at length in HIV, other cortical abnormalities 
have been observed that could impact HIV NCI. Cortical thinning has been observed in temporal 
(143), sensory, and motor cortices in PLWH (136). Poorer fine motor performance associated with 
reduced cerebral blood flow in occipital cortex in a study of PLWH on protease inhibitor 
monotherapy (144). Altered fMRI signal in anterior cingulate cortex associates with executive 
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function deficits in cART-treated PLWH (145), and volume loss has also been reported in cingulate 
cortices in PLWH (143, 146). Microglial activation in the posterior cingulate cortex associates with 
poorer executive function in cART-treated PLWH (147). Abnormalities in additional sub-cortical 
regions beyond striatum/basal ganglia (caudate, putamen, globus pallidus) have also been 
reported in PLWH, including the amygdala (146). Atrophy of the brainstem and cerebellum has also 
been observed in PLWH (134, 148). Finally, white matter abnormalities are frequently observed in 
HIV and associate with neuroinflammation and HIV NCI (149-152). Together, these data indicate it 
is valuable to study regions whose functions reflect a range of neurocognitive domains to identify 
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2.1 Abstract  
Previous studies showed that persons living with HIV (PLWH) demonstrate higher brain prefrontal 
cortex neuroinflammation and immunoproteasome expression compared to HIV-negative 
individuals; these associate positively with HIV levels. Lower expression of the antioxidant enzyme 
heme oxygenase-1 (HO-1) was observed in PLWH with HIV-associated neurocognitive impairment 
(NCI) compared to neurocognitively normal PLWH. We hypothesized that similar expression 
patterns occur throughout cortical, sub-cortical and brainstem regions in PLWH, and that 
neuroinflammation and immunoproteasome expression associate with lower expression of 
neuronal markers. We analyzed autopsied brains (15 regions) from 9 PLWH without HIV NCI and 
7 matched HIV-negative individuals. Using Western blot and RT-qPCR, we quantified synaptic, 
inflammatory, immunoproteasome, endothelial, and antioxidant biomarkers, including HO-1 and its 
isoform heme oxygenase-2 (HO-2). In these PLWH without HIV NCI, we observed higher 
expression of neuroinflammatory, endothelial, and immunoproteasome markers in multiple cortical 
and sub-cortical regions compared to HIV-negative individuals, suggesting a global brain 
inflammatory response to HIV. Several regions, including posterior cingulate cortex, globus 
pallidus, and cerebellum showed a distinct pattern of higher type I interferon (IFN)-stimulated gene 
and immunoproteasome expression. PLWH without HIV NCI also had i) stable or higher HO-1 
expression; and positive associations between ii) HO-1 and HIV levels (CSF, plasma); and iii) HO-
1 expression and neuroinflammation, in multiple cortical, sub-cortical and brainstem regions. We 
observed no differences in synaptic marker expression, suggesting little, if any, associated 
neuronal injury. We speculate that this may reflect a neuroprotective effect of a concurrent HO-1 





Persistent oxidative stress and inflammation within the brain of persons living with HIV (PLWH) are 
thought to contribute to development of HIV-associated neurocognitive impairment (HIV NCI) (9, 
31, 153-156). In the absence of HIV infection, such potentially pathological processes typically 
induce expression of antioxidant response genes, which execute cytoprotective responses to acute 
cellular injury in the brain. Among those most strongly linked to neuronal injury and recovery in 
various models is the antioxidant/anti-inflammatory enzyme, heme oxygenase (HO), which exists 
in two isoforms, heme oxygenase-1 and -2 (HO-1, HO-2) (97, 118, 157-160). HO-1 is highly 
inducible by a variety of factors and predominates in non-neuronal cells, while HO-2 is considered 
to be constitutively expressed and only slowly inducible by a few factors. In the brain, HO-2 
predominates in neurons. The protective effects of HO-1 and HO-2 are downstream of their 
selective catabolism of heme, a highly toxic, pro-oxidative factor. Heme is released as a byproduct 
of hemoglobin degradation, or, in the context of cellular stress, from cellular metabolic enzymes for 
which it serves as a critical cofactor. HO-mediated heme catabolism produces the anti-
inflammatory, cytoprotective metabolites carbon monoxide and bilirubin (98, 161-163). In the 
human brain, expression of HO-1 and HO-2 RNA is reportedly higher in cortical areas (frontal, 
temporal, occipital) compared to pons and cerebellum (164), which suggests that HO enzymatic 
cytoprotective capacity may vary among brain regions.  
 
We previously demonstrated that decreased HO-1 protein expression in the prefrontal cortex of 
PLWH associates with HIV NCI and encephalitis, and that this HO-1 reduction is associated with 
the level of HIV expression, type I interferon (IFN)-stimulated gene expression, and macrophage 
activation (36, 165). Notably, we observed a marked discordance (negative association) between 
HO-1 protein and RNA expression, which suggests post-transcriptional loss of HO-1 protein (104). 
In in vitro studies, we linked HO-1 expression to dysregulation of glutamate release from glial cells, 
further suggesting a direct link between HO-1 deficiency and excitotoxic injury as a mechanism of 
HIV-induced neuronal injury in vivo (165, 166). HO-1 protein reduction was also observed in the 
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striatum, but not in the occipital cortex or cerebellum, which suggests regional brain variability in 
HO-1 expression in response to HIV infection. Upregulation of IFN-stimulated genes and 
endothelia-associated genes have also been reported in the striatum in PLWH, which suggests 
concurrent host antioxidant responses and neuroinflammatory responses that extend beyond the 
prefrontal cortex (46). 
 
We addressed several potential mechanisms by which HO-1 expression might be reduced by HIV 
infection in PLWH. PLWH have increased immunoproteasome subunit expression in prefrontal 
cortex that associates with HIV load, HIV NCI and HIV-encephalitis (105). We found evidence in 
vitro that degradation of HO-1, but not HO-2, is enhanced through IFN-induced immunoproteasome 
expression (104), thus potentially explaining the observed discordance between HO-1 protein and 
RNA expression in the prefrontal cortex of PLWH. We also addressed the potential role for known 
regulatory variations in the HO-1 promoter region [a (GT)n dinucleotide repeat polymorphism]. We 
found significant associations between this polymorphism and type I IFN-stimulated genes and T-
lymphocyte activation within the prefrontal cortex of PLWH (114). In a separate clinical cohort study 
of PLWH, we observed modulating effects of the HO-1 (GT)n promoter dinucleotide repeat on risk 
for HIV NCI (115). These observations suggest a balance between transcriptional and post-
translational mechanisms of HO-1 modulation that determine parenchymal HO-1 levels in the 
setting of neuroinflammation in prefrontal cortex, and they also suggest a role for HO-1 expression 
in modulating risk for HIV NCI. 
 
In this study, we sought to determine whether neuroinflammation and a concurrent HO-1 
antioxidant response in PLWH extend to additional cortical and deep brain regions, and whether 
those processes associate with synaptic integrity. We analyzed 15 brain regions in an autopsy 
cohort of PLWH without HIV NCI (n=9) and HIV-negative individuals (n=7). We determined 
expression of HO-1 and HO-2, and defined their associations with plasma and cerebrospinal fluid 
(CSF) HIV levels, markers of neuroinflammation, synaptic integrity, endothelial adhesion, and 
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immunoproteasome expression. Similar to our prior observations in prefrontal cortex of PLWH, we 
observed higher expression of markers of neuroinflammation, endothelial activation and adhesion, 
and immunoproteasome expression in multiple cortical, sub-cortical and brainstem regions 
compared to HIV-negative individuals. Notably, posterior cingulate cortex, globus pallidus, and 
cerebellum expressed similar neuroinflammatory patterns. We also observed i) similar or increased 
HO-1 expression levels in all brain regions in PLWH compared to HIV-negative individuals; ii) 
positive association between HO-1 expression and HIV levels in CSF and plasma; iii) positive 
association between HO-1 and neuroinflammatory markers; and iv) no difference in expression of 
synaptic markers.  
 
2.3 Materials and Methods 
National NeuroAIDS Tissue Consortium brain autopsy cohort and viral loads 
A cohort consisting of 9 PLWH and 7 HIV-negative individuals was selected from the National 
NeuroAIDS Tissue Consortium (NNTC) (Table 2.1). We selected individuals on the basis of several 
criteria: i) the availability of brain tissue specimens from multiple brain regions; ii) absence of 
neurocognitive impairment attributable to HIV infection (i.e., HIV NCI) and HIV encephalitis; and, if 
possible, iii) homozygosity for either ‘short’ (S/S) or ‘long’ (L/L) HO-1 promoter region (GT)n 
dinucleotide repeat allele genotype. The rationale for seeking individuals with either the S/S or L/L 
genotype is that HMOX1 promoters with short HO-1 (GT)n repeats express higher basal HMOX1 
gene transcriptional activity and inducibility (89, 90, 110, 113), and short HO-1 (GT)n repeat alleles 
associate with less brain inflammation and lower risk for HIV NCI in PLWH (114). This could 
potentially allow us to identify differences in HO-1 protein expression in various brain regions on 
the basis of the individual’s promoter genotype in the presence and absence of HIV infection.  
 
Among the 9 PLWH studied, none had diagnosed HIV NCI, according to the Frascati Criteria (11). 
Four were categorized as “Neuropsychological impairment-other (NPIO),” indicating impairment 
that can be attributed to another comorbid condition distinct from HIV infection or AIDS-related CNS 
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disease (co-infection, tumor, metabolic disease, other acquired neurological disease). The 
remaining 5 PLWH were categorized as neurocognitively normal. Eight of the PLWH were 
antiretroviral therapy (ART)-experienced. PLWH and HIV-negative individuals (n=7) did not differ 
significantly by age, sex, race, ethnicity, or postmortem autopsy interval. Blood (n=9) and CSF 
(n=6) samples were obtained within 6 months of death and on the same day that neurocognitive 
testing was completed. Plasma and CSF HIV RNA levels were determined with the Amplicor HIV-
1 Monitor test v1.1 through v1.5 (Roche). 
 
Monocyte-derived macrophage culture and siRNA transfection 
Peripheral blood mononuclear cells (PBMC) were isolated from volunteer donors by Ficoll density 
gradient centrifugation, and monocytes were isolated by adherence to gelatin-coated flasks (167). 
Isolated monocytes were plated at 10.5x104 cells/cm3 on Cell-Bind plates (Corning) and cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum 
(Thermo Scientific), 10% horse serum (Invitrogen), 1% non-essential amino acids (Invitrogen), 
2mM glutamine (Invitrogen), and 50U/ml penicillin/streptomycin at 37ºC, 6% CO2. Monocyte-
derived macrophages (MDM) were cultured for 7 days in vitro and inspected for differentiation. 
Silencer® Select siRNAs (Ambion) were transfected at a final concentration of 20nM using 
Lipofectamine RNAiMax (Invitrogen).  
 
Brain tissue sampling 
Fresh frozen brain tissue samples from frontal cortex (FC), temporal cortex (TC), occipital cortex 
(OC), motor cortex (MC), sensory cortex (SC), anterior cingulate cortex (ACC), posterior cingulate 
cortex (PCC), amygdala (AM), caudate nucleus/putamen (CN), globus pallidus (GP), pons (PN), 
midbrain (MB), medulla (MED), cerebellum (CB), frontal white matter (FWM), and spinal cord (SPC) 
(Table 2.2) stored at -80°C were dissected on dry ice. Samples from each region were divided into 





Protein lysates were prepared from 100mg of tissue homogenized by silica bead beating and 
sonication in 7 volumes of buffer (10mM Tris-HCl pH 7.8, 0.5mM Dithiothreitol [DTT], 5mM MgCl2, 
0.03% Triton X-100) containing Complete Protease Inhibitor Cocktail (Roche Applied Science) and 
PhosSTOP Phosphatase Inhibitor Cocktail (Roche). Protein concentration was quantified using the 
Detergent Compatible (DC) protein assay (BioRad). Proteins were resolved by SDS-PAGE and 
transferred to polyvinylidene fluoride (PVDF) membranes. Membranes were incubated with primary 
antibody (Table 2.3) overnight at 4°C. For infrared fluorescent detection of protein expression, 
membranes were incubated with IRDye-conjugated secondary antibody (Table 2.4) for one hour 
at room temperature and scanned with the Odyssey CLx Infrared Imagine System (LI-COR 
Biosciences). Background-corrected signal intensity of protein bands was measured using Image 
Studio Lite software (LI-COR Biosciences).  
 
HO-1 promoter (GT)n repeat genotyping 
HO-1 (GT)n repeat lengths were determined by PCR of the (GT)n repeat region with a 6-FAM 
labeled forward primer, followed by fragment size determination on a capillary sequencer. In a 
subset of samples, PCR products were run on a 2% agarose gel to assess amplification of the 
target sequence predicted sizes (homozygotes, heterozygotes). All samples were run at least twice 
from independent PCR reactions to ensure accurate and reproducible sizing and were determined 
to be accurate within +/- 1 GT repeats. In rare (<4%) cases where identical (GT)n repeat lengths 
were not obtained in duplicate, samples were run additional times to confirm accurate repeat 
lengths. We assigned HO-1 (GT)n alleles as short ‘S’ (< 27), medium ‘M’ (27-34) or long ‘L’ (> 34) 
(GT)n repeats (114). 
 
In-gel digestion and mass spectrometry analysis and confirmation of HO-1 detection 
Human brain lysates were resolved by SDS-PAGE, with an identical lysate added to two lanes of 
a symmetrically organized gel. One half of the gel was stained for protein with Coomassie blue, 
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while the other half was transferred to PVDF membrane and probed for HO-1 as described above. 
Gel bands for digestion were chosen by exact size according to corresponding bands recognized 
by the primary antibody used to probe the PVDF membrane. Each gel band was excised and further 
cut into 1 mm cubes (168). These were de-stained with 50% Methanol/1.25% Acetic Acid, reduced 
with 5mM Dithiothreitol (DTT) (Thermo), and alkylated with 20mM iodoacetamide (Sigma). Gel 
pieces were then washed with 20mM ammonium bicarbonate (Sigma) and dehydrated with 
acetonitrile (Fisher). Trypsin (Promega) (5ng/mL in 20mM ammonium bicarbonate) was added to 
the gel pieces and proteolysis was allowed to proceed overnight at 37ºC. Peptides were extracted 
with 0.3% triflouroacetic acid (J.T. Baker), followed by 50% acetonitrile. Extracts were combined 
and the volume was reduced by vacuum centrifugation. 
 
Extracted samples were analyzed on a QExactive HF mass spectrometer (Thermofisher Scientific 
San Jose, CA) coupled with an Ultimate 3000 nano UPLC system and an EasySpray source. 
Peptides were separated by reverse phase (RP)-HPLC on Easy-Spray RSLC C18 2μm 75μm id × 
50cm column at 50C. Mobile phase A consisted of 0.1% formic acid and mobile phase B of 0.1% 
formic acid/acetonitrile. Peptides were eluted into the mass spectrometer at 210nL/min with each 
RP-LC run comprising a 125-minute gradient from 1 to 5 % B in 15 min, 5-45%B in 110 min. The 
mass spectrometer was set to repetitively scan m/z from 300 to 1400 (R=240,000) followed by 
data-dependent MS/MS scans on the twenty most abundant ions, minimum AGC 1e4, dynamic 
exclusion with a repeat count of 1, repeat duration of 30s, (R=15000) FTMS full scan AGC target 
value was 3e6, while MSn AGC was 1e5, respectively. MSn injection time was 160 ms; microscans 
were set at one. Rejection of unassigned and 1+,6-8 charge states was set.  
 
Peptide and protein identification were performed with the Sequest search engine accessed 
through Proteome Discoverer 2.0 (Thermo Fisher Scientific) using human reference proteome 
database from Uniprot (canonical and isoform proteins; downloaded on 20180104). 
Carbamidomethyl of Cys was defined as a fixed modification. Oxidation of Met and acetylation of 
protein N-termini were set as variable modifications. Trypsin was selected as the digestion enzyme, 
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and a maximum of two missed cleavages per peptide was allowed. The precursor mass tolerance 
was set at 10 ppm and the MS/MS fragment mass tolerance was set at 0.02 DA. The minimum 
peptide length was set at 7 amino acids. The False Discovery Rate (FDR) for peptides and proteins 
was set at 1%. The rest of the parameters were kept as default. The search results were exported 
and visualized in Scaffold 4.8.4 (Proteome Software). Mass spectrometry analysis and data 
processing were performed with support of the Children’s Hospital of Philadelphia Proteomics Core. 
 
Quantitative real-time qPCR (qPCR) 
Total RNA was prepared from 50mg of fresh-frozen brain tissue (adjacent to tissue section used 
for preparation of protein lysates) using the RNeasy Lipid Tissue Mini Kit. RNA purity and 
concentration were determined with NanoDrop One UV-Vis spectrophotometer (ThermoFisher 
Scientific) and 1μg of total RNA was reverse transcribed to single-stranded cDNA using the High 
Capacity RNA-to-cDNA Kit (Applied Biosciences). Relative RNA expression was determined by 
qPCR using 25ng cDNA, Taqman Fast Universal Master Mix (Applied Biosciences) and TaqMan 
primer/probe sets (HMOX1: Hs01110250_m1; GAPDH: Hs02786624_g1; ISG15: 
Ha00192713_m1; MX1: Hs00182073_m1; Applied Biosystems) in 10μL reaction volumes. 
Reactions were run in triplicate on a StepOnePlus (ThermoFisher Scientific). GAPDH was used as 
the reference gene and RNA expression was calculated for each sample relative to the average 
expression of that gene across all brain samples. 
 
Statistical analysis 
All quantifications are expressed as mean ± standard error of the mean (SEM). Protein and RNA 
expression data were log transformed. Differences in expression of markers within individual brain 
regions between HIV-negative individuals and PLWH were evaluated by Student’s unpaired t-test. 
Differences in mean expression of markers throughout the brain between HIV-negative individuals 
and PLWH were analyzed by Student’s paired t-test, whereby mean expression of a marker in a 
given region within HIV-negative individuals was paired with mean expression of that marker in the 
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same region within PLWH. Linear trends were analyzed by Pearson’s correlation with line of best 
fit determined by linear regression. Statistical significance was defined as p<0.05. All statistical 
tests were performed using GraphPad Prism version 8. 
 
2.4 Results  
HO-1 expression in multiple brain regions associates with CSF and plasma HIV levels in PLWH  
We previously showed that HO-1 protein levels are lower in prefrontal cortex and caudate of PLWH 
with HIV NCI compared to HIV-negative individuals while HO-1 RNA levels are higher, suggesting 
an induction of HO-1 gene expression associated with post-translational HO-1 protein loss that 
may contribute to HIV NCI (36). No such pattern was seen in occipital cortex or cerebellum. In this 
study, we examined a broad distribution of brain regions (15 regions) and spinal cord in PLWH 
without HIV NCI. We confirmed the relative specificity of the anti-HO-1 antibody used for our 
analyses (Fig. 2.1). We analyzed human and transgenic mouse brain and spleen lysates (Fig. 
2.1A, C, D) and used mass spectrometry (Fig. 2.1B) to confirm antibody specificity for HO-1 in 
human brain tissue. Comparing HO-1 protein expression within each brain region, we found higher 
HO-1 levels only in the midbrain in PLWH compared to HIV-negative individuals (Fig. 2.2A). 
However, the average of the means of HO-1 protein expression by region was significantly higher 
in PLWH, suggesting that increased HO-1 expression likely occurs in multiple brain regions (Fig. 
2.2B). We also observed a positive association between HO-1 RNA and HO-1 protein expression 
in PLWH in 7 of 15 brain regions analyzed (temporal cortex, occipital cortex, motor cortex, sensory 
cortex, anterior cingulate cortex, posterior cingulate cortex, frontal white matter; Table 2.5).  
 
Detection of CSF HIV RNA was successful in 6 of 9 PLWH while brain parenchymal HIV RNA was 
not detected in 8 of 9 PLWH, precluding comprehensive analysis of HIV levels in brain parenchyma. 
Nonetheless, CSF HIV RNA associated positively with brain HO-1 RNA, in 9 of 15 brain regions, 
including frontal cortex (Fig. 2.2C), five other cortical regions, amygdala, globus pallidus, and 
cerebellum (Table 2.6), similar to our prior observations in prefrontal cortex (36). We also found 
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positive associations between plasma HIV RNA and HO-1 RNA in all brain regions except midbrain 
and frontal white matter (Fig. 2.2D, Table 2.6). CSF HIV RNA associated positively with HO-1 
protein expression in 5 of 15 brain regions, including frontal cortex (Fig. 2.2E), and four other 
cortical regions (Table 2.6). Finally, we observed positive associations between plasma HIV RNA 
and HO-1 protein in 7 of 15 brain regions, including frontal cortex (Fig. 2.2F), five other cortical 
regions, and the pons (Table 2.6). These results confirm positive associations between plasma 
and CSF HIV expression and the host HO-1 response in multiple brain regions. 
 
Expression of the constitutive HO-2 isoform is higher in frontal white matter in PLWH than in HIV-
negative individuals 
The HO-2 isoform is considered to be constitutively expressed, but expression can change in 
response to certain stimuli (hypoxia, glucocorticoids) (93-95, 169). In contrast to HO-1 expression 
in the brain, HO-2 is the predominant isoform expressed in neurons. We observed significantly 
higher HO-2 expression only in frontal white matter in PLWH compared to HIV-negative individuals 
(Fig. 2.3A). However, similar to our HO-1 expression observation (Fig. 2.2B), when we compared 
the means of HO-2 expression for each region we found higher HO-2 expression in PLWH (Fig. 
2.3B). 
 
Immunoproteasome expression is higher in multiple brain regions in PLWH than in HIV-negative 
individuals 
Our prior studies of PLWH showed increased immunoproteasome expression in the prefrontal 
cortex that associates with HIV NCI and HIV encephalitis (105). We also showed a negative 
association between HO-1 protein and immunoproteasome expression in prefrontal cortex in 
PLWH and evidence for immunoproteasome-associated degradation of HO-1 (104). To determine 
whether this association is consistent throughout the brain in PLWH, we quantified expression of 
immunoproteasomes (LMP7 and Pa28a subunits) and constitutive proteasomes (b5 subunit) in 




HIV infection associated with higher expression of immunoproteasome subunits in multiple cortical 
and sub-cortical regions (LMP7: temporal cortex, occipital cortex, sensory cortex, posterior 
cingulate cortex, globus pallidus, cerebellum, frontal white matter; Pa28a: temporal cortex, sensory 
cortex, posterior cingulate cortex, globus pallidus, cerebellum; Fig. 2.4A-D). These 
immunoproteasome associations stand in contrast to the lack of changes in constitutive 
proteasome expression (b5 subunit), in PLWH compared to HIV-negative individuals with the 
exception of lower b5 expression in the pons (Fig. 2.4E-F). We did not find a consistent relationship 
between HO-1 and LMP7 expression across brain regions in PLWH (Table 2.7).  
 
HO-1 expression in multiple brain regions associates with type I IFN-stimulated genes in PLWH 
We next determined the association between HIV infection, type I IFN-stimulated genes (ISG15 
and MX1), and HO-1 expression. We found increased type I IFN-stimulated gene expression in 
multiple cortical and sub-cortical regions (Fig. 2.5A-D). We observed higher MX1 ([Fig. 2.5A-B]: 
frontal and posterior cingulate cortices, globus pallidus, cerebellum, and frontal white matter) and 
higher ISG15 ([Fig. 2.5C-D]: frontal cortex and frontal white matter). We also identified several 
positive associations between ISG15 and i) HO-1 RNA (temporal cortex, anterior and posterior 
cingulate cortices, frontal white matter [Table 2.8]); ii) HO-1 protein (anterior cingulate cortex, 
amygdala, frontal white matter, spinal cord [Table 2.8]) in PLWH. MX1 also associated positively 
with HO-1 RNA: temporal, occipital, anterior cingulate cortices, amygdala, cerebellum, frontal white 
matter, spinal cord (Table 2.8) in PLWH. In contrast, in HIV-negative individuals, we did not find 
clear evidence of an association between HO-1 and ISG15 or MX1 (Table 2.9). 
 
HO-1 expression in multiple brain regions associates with markers of endothelial activation and 
adhesion in PLWH  
Dysfunction and/or injury to the neurovascular unit (defined as capillary endothelia, pericytes, 
astrocytic foot processes, neuronal processes, perivascular macrophages, along with the CNS 
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extracellular space, subarachnoid space, and blood plasma) is thought to be a major contributor to 
the development of HIV NCI, perhaps independently from brain neuroinflammation (10, 46, 60, 
170). We examined several endothelial adhesion molecules (ICAM-1, VCAM-1, PECAM-1) and 
observed higher expression of each overall, and in multiple cortical and sub-cortical regions in 
PLWH compared to HIV-negative individuals: i) ICAM-1: frontal, sensory, and temporal cortices, 
and cerebellum (Fig. 2.6A-B); ii) VCAM-1: motor cortex and globus pallidus (Fig. 2.6C-D); and iii) 
PECAM-1: anterior cingulate cortex (Fig. 2.6E-F).  
 
We determined the associations of these endothelial markers with HO-1 expression. VCAM-1 and 
PECAM-1, but not ICAM-1, associated positively with HO-1 protein expression in PLWH in multiple 
cortical, sub-cortical and brainstem regions (VCAM-1: frontal, temporal, anterior cingulate cortices, 
pons, midbrain, spinal cord; PECAM-1: temporal, occipital and posterior cingulate cortices, globus 
pallidus [Table 2.10]). Each also associated positively with HO-1 RNA in multiple cortical, sub-
cortical and brainstem regions in PLWH (VCAM-1: amygdala, caudate; PECAM-1: six cortical 
regions, caudate, pons [Table 2.10]). We did not find consistent associations between HO-1 and 
endothelial adhesion molecules in HIV-negative individuals (Table 2.11).  
 
Synaptic marker expression in multiple brain regions is similar in PLWH and in HIV-negative 
individuals 
Because the induction of HO-1 expression is associated with neuroprotection in various injury 
response models including HIV infection (36, 166), we measured markers of synaptic integrity in 
PLWH. To do this, we analyzed expression of presynaptic (synaptophysin) and postsynaptic 
(PSD95) markers. Expression of each was similar in PLWH compared to HIV-negative individuals 
(Fig. 2.7A-D) and neither associated with HO-1 protein or RNA expression in PLWH (Tables 2.12-
13).  
 
The HO-1 promoter region (GT)n variant genotype does not associate with brain HO-1 expression 
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The HO-1 promoter region contains a (GT)n dinucleotide repeat that modulates basal HO-1 
expression and gene inducibility, specifically with shorter HO-1 (GT)n repeats associating with 
higher basal HO-1 promoter activity (89, 90, 110, 113), as well as better outcomes in inflammatory 
and oxidative stress-associated diseases (107, 108, 110, 111, 113). Short (S) (GT)n repeat length 
alleles are defined as those with less than 27 (GT)n repeats, while long (L) alleles are defined as 
those with more than 34 (GT)n repeats (114, 171, 172). Our current study cohort included 5 ‘SS’ 
homozygous individuals (3 PLWH, 2 HIV-negative) and 4 ‘LL’ homozygous individuals (3 PLWH, 1 
HIV-negative). We did not find a significant difference in HO-1 protein or RNA expression in any 
individual brain region in PLWH based upon HO-1 (GT)n repeat allele genotype (Fig. 2.8A-B).  
 
2.5 Discussion 
Neuroinflammation and oxidative stress are considered central to the pathogenesis of 
neurocognitive impairment in PLWH and analyses of associated biomarkers are typically limited to 
only a few brain regions. In previous studies of prefrontal cortex in PLWH compared to HIV-negative 
individuals, we and others observed increased expression of markers of neuroinflammation (IFN-
stimulated genes, endothelial markers) and immunoproteasome expression that associate with HIV 
NCI and HIV-encephalitis (46, 105, 173, 174). In prefrontal cortex, we also observed reduced 
protein levels of the antioxidant/anti-inflammatory enzyme, HO-1 (36); despite increased levels of 
HO-1 RNA (104). This discordant HO-1 protein and RNA expression associated with HIV load in 
brain and CSF, neuroinflammation, immunoproteasome expression, and HIV NCI. Notably, PLWH 
with HIV NCI had significantly lower HO-1 expression in prefrontal cortex compared to PLWH 
without HIV NCI in the same cohort. In in vitro studies, we showed that HIV infection drives 
decreased HO-1 expression in monocyte-derived macrophages, and that immunoproteasome 
expression enhances HO-1 degradation (36, 104). We subsequently linked this reduced glial cell 
HO-1 expression with release of neurotoxic levels of glutamate, which has been associated with 
HIV NCI (46, 165, 175-182). We concluded that HIV infection and HIV-driven neuroinflammation 
and immunoproteasome induction could lead to accelerated HO-1 protein degradation and loss, 
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leading to neuronal injury and, ultimately, HIV NCI. Finally, we also showed that the HO-1 gene 
promoter region (GT)n dinucleotide repeat genetic variation, which is known to modulate HO-1 
transcriptional activity, associates with risk for HIV NCI and neuroinflammation in PLWH in a pattern 
consistent with a role for HO-1 in reducing risk for HIV NCI (114, 115).  
 
We thus hypothesized that PLWH have HIV-driven neuroinflammation and immunoproteasome 
expression throughout the brain that associates with HO-1 expression, and that this might associate 
with synaptic integrity in multiple regions, or even predominantly in selected regions. Based upon 
our prior observations in prefrontal cortex comparing PLWH with and without HIV NCI and abundant 
literature defining HO-1 induction in response to inflammation and oxidative stress, we 
hypothesized that this cohort of PLWH without HIV NCI would have normal or even increased levels 
of brain HO-1 expression along with increased neuroinflammation and immunoproteasome 
expression. Our results indeed showed stable or increased HO-1 expression, and increased 
neuroinflammation, endothelial marker expression, and immunoproteasome expression in multiple 
cortical, sub-cortical, and brainstem regions in PLWH compared to HIV-negative individuals (see 
schematic Fig. 2.9). We felt that examining individuals with predictably distinct HO-1 (GT)n 
genotypes might allow us to identify differences in regional brain HO-1 expression that might be 
influenced by the individual’s promoter genotype translational HO-1 expression capacity, both in 
the presence and absence of HIV infection. However, we could identify only 6 PLWH individuals of 
‘SS’ and ‘LL’ allele genotypes who met all three inclusion criteria. Among the HIV-negative 
individuals, 3 had these genotypes, thus limiting the statistical powering of the analysis.  
 
The observed stable or increased HO-1 expression in PLWH without HIV NCI is in contrast to our 
previously reported decreased HO-1 expression in prefrontal cortex in PLWH with HIV NCI. These 
data suggest that although induction of pathological neuroinflammation occurs in multiple brain 
regions, induction of a protective HO-1 response also occurs in such regions in PLWH without HIV 
NCI. These data also suggest that the HO-1 response is pathologically suppressed in PLWH who 
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develop HIV NCI, in part through immunoproteasome-mediated degradation of HO-1 (104). Thus, 
in conjunction with our previous findings, this study is consistent with the hypothesis that 
therapeutic induction of HO-1 in PLWH may limit neuroinflammation and provide neuroprotection 
against HIV NCI (see schematic Fig. 2.9). We did not observe differences in synaptic marker 
expression in this cohort, which suggests that these concurrent inflammatory and antioxidant 
responses were not associated with synaptic neuronal injury in these individuals, albeit as 
determined only by the level of sensitivity of detection of differences in expression levels of synaptic 
proteins. 
 
We also noted some specific differences in these responses among different brain regions and we 
speculate that there are likely functional consequences, as has been suggested in previous studies 
of PLWH (183-190). While immunoproteasome subunit expression (LMP7, Pa28a) was higher in 
7/15 brain regions, three of these regions (globus pallidus, cerebellum, and posterior cingulate 
cortex [PCC]) also showed significantly higher type I IFN-stimulated gene expression (MX1).  
 
We speculate that our data reflect particular vulnerability of the PCC to HIV-induced 
neuroinflammation, which could have consequences for neurocognitive functioning. The 
prevalence of deficits in executive functioning is high in PLWH, even in those not meeting the full 
diagnostic criteria for HIV NCI (133) Indeed, functional neuroimaging studies have identified 
metabolic abnormalities in the PCC that associate with HIV infection and with progression of HIV 
NCI, as well as abnormal aging and amyloid pathology in the HIV-negative population (186, 191, 
192). In a previous study of PLWH, microglial activation in PCC associated specifically with poorer 
executive function, suggesting clinical significance to neuroinflammation in that region even in 
PLWH who do not meet the strict Frascati criteria for the diagnosis of HIV NCI (193). Cysique et al 
(186, 188) used Magnetic Resonance Spectroscopy to detect neuronal injury (reduced N-acetyl-
aspartate/NAA) and neuroinflammation (increased myoinositol/mI) in PCC in virally-suppressed 
PLWH compared to HIV-negative individuals. However, we cannot attribute deficits in executive 
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function solely to involvement of the PCC in our PLWH cohort, as such dysfunction is also affected 
by other brain regions, including frontal cortex and white matter, precuneus, accumbens, putamen, 
and globus pallidus (133, 189). 
 
Other sub-cortical brain regions have also been implicated in selective vulnerability to HIV and 
associated NCI. Vulnerability of the striatum (caudate + putamen) to HIV-associated blood-brain 
barrier disruption and impaired function has been observed, especially in individuals with HIV-
associated dementia and HIV-encephalitis (56, 140, 194-197). Our study also implicates the globus 
pallidus, which, along with caudate and putamen, show neuroinflammation (microglial activation) 
in PLWH despite suppressive combination antiretroviral therapy (198). Similar to our findings in the 
PCC, our data demonstrate neuroinflammation (MX1) and immunoproteasome expression (LMP7, 
Pa28a) in globus pallidus, extending neuropathological observations to this region within the basal 
ganglia (caudate + putamen + globus pallidus), and they further suggest its potential vulnerability 
to neuroinflammation in PLWH. Although we cannot specifically link our globus pallidus findings to 
NCI in our PLWH cohort, the links between basal ganglia dysfunction, neuroinflammation and HIV 
NCI are the subject of many studies (128, 132, 199-203). Finally, cerebellar atrophy, degeneration, 
and decreased functional connectivity have also been reported in PLWH (204-206).  
 
Whether the specific neuroinflammatory changes (type I IFN-stimulated genes, endothelial 
activation) or immunoproteasome induction identified in this study contribute specifically to 
dysfunction in these brain regions in PLWH will require further investigation. We speculate that the 
increase of endothelial adhesion molecules might promote increased immune cell adhesion and 
migration through the blood-brain barrier, which could promote local neuroinflammation. The 
clustering of ICAM-1 and VCAM-1 at the apical surface of endothelial cells and facilitation of 
leukocyte adhesion prior to diapedesis is well known (207-211). Expression of type I IFN (IFNa) 
has been linked to HIV NCI presumably by promoting a pro-inflammatory state (212). Finally, 
increased immunoproteasome expression in the prefrontal cortex in PLWH is associated with HIV 
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NCI (104, 105, 174), and increased immunoproteasome expression is associated with enhanced 
autoimmunity and neurodegeneration in other CNS disease states (213, 214). In total, our data 
suggest that HIV infection of the brain broadly induces neuroinflammatory responses and 
antioxidant responses that are more pronounced in certain regions, which may promote more 
global or more regionally-influenced features of NCI, respectively.  
 
We have demonstrated expression of neuroinflammatory and immunoproteasome markers that 
associate with expression of the antioxidant response (HO-1 expression) in multiple cortical, sub-
cortical and brainstem regions in PLWH without HIV NCI. These observations extend previous 
findings of HIV-associated responses in the prefrontal cortex, and they suggest a ubiquitous 
response pattern throughout the brain to HIV infection. We speculate that the absence of synaptic 
protein loss in the setting of neuroinflammation may reflect a protective effect of the antioxidant 
response. We further speculate that more robust regional responses, such as those within the PCC, 
globus pallidus, and cerebellum might disrupt normal circuitry, with effects that may be detected 
only with more selective clinical assessments targeting such regions. Finally, we speculate that 
targeting the regulation of the HO-1 antioxidant response might offer therapeutic options for 
neuroprotection against HIV throughout the brain. 
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Figure 2.1 Validation of a rabbit polyclonal HO-1 antibody for Western blot 
 (A) Human brain tissue lysates were probed for b-tubulin and HO-1 (Enzo ADI-SPA-895) by 
Western blot. For a control comparator, we used differentiated human monocyte-derived 
macrophages (MDMs), which express high levels of HO-1 after siRNA knock-down of the Nrf2 
repressor protein BACH-1 (36, 215). MDMs were treated with siRNAs targeting HO-1 or BACH1 
for 6 days. In human brain lysates, we observed two bands at ~32kDa (white and black arrows), of 
which the higher molecular weight band (white arrow) was consistently more intense. In human 
MDMs, we observed the same two bands, but only the lower molecular weight band (black arrow) 
was enhanced as expected by anti-BACH1 siRNA transfection. (B) Human brain lysate was 
resolved by SDS-PAGE in two identically loaded lanes. One half of SDS-PAGE gel was stained 
with Coomassie blue (left) and the other was transferred to PVDF membrane and probed for HO-
1 with ADI-SPA-895 (right). Two bands were dissected from the stained gel (left) based on location 
of bands in 32kDa range on the membrane (white and black arrows), trypsin-digested, and 
subjected to mass spectrometric analysis. Sequence-to-spectrum peptide assignments generated 
by SEQUEST in Proteome Discoverer were loaded into Scaffold to validate MS/MS peptide and 
protein identification. Four unique peptides with Xcorr scores >2.0 and delta Cn >0.1 representing 
21% coverage of the HO1 sequence were identified in the two gel bands. Each MS/MS spectrum 
was also manually evaluated and contained contiguous series of y-series fragment ions. (C) Human 
and wild-type C57Bl/6 (WT), HO-1 knockout (HO-1 KO), and human HO-1 overexpressing (HO-1 
hBAC) mouse brain and spleen lysates (courtesy of Dr. Anupam Agarwal, UAB) were probed for 
b-tubulin and HO-1 using Enzo ADI-SPA-895. Two bands were detected at ~32kDa in human brain 
tissue lysates (white and black arrows), and a similar banding pattern was observed in transgenic 
mouse brain tissue lysates. The higher molecular weight band (white arrow) was detected in HO-1 
knockout mouse brain tissue lysates, indicating a protein other than HO-1 at 32kDa. No such band 
was observed in spleen lysates from mouse or human, or in the HO-1 knockout mouse lysates. 
These results suggest that ADI-SPA-895 detects HO-1 protein in both bands, as well as another 
protein in the higher molecular weight band. (D) Human and wild-type C57Bl/6 (WT), HO-1 
41 
 
knockout (HO-1 KO), and human HO-1 overexpressing (HO-1 hBAC) mouse brain and spleen 
lysates were probed for b-tubulin and HO-1 using Enzo ADI-SPA-894. A single band was detected 
at 32kDa in mouse brain tissue lysates (black arrow), which was not present in HO-1 knockout 
mouse brain or spleen. We confirmed HO-1 content in this band, and therefore used this antibody 




Figure 2.2 HO-1 expression in multiple cortical and deep brain regions associates with CSF 
and plasma HIV levels in PLWH 
HO-1 protein (A-B, E-F) and RNA (C-D) were measured by Western blot and RT-qPCR, 
respectively. (A) Effect of HIV infection on HO-1 expression in individual brain regions was 
measured by Student’s unpaired t-test. (B) Effect of HIV infection on whole brain HO-1 expression 
was measured by Student’s paired t-test, where the mean expression of HO-1 in each region in 
HIV-negative individuals was compared to the mean expression of HO-1 that region in in PLWH. 
(C, E) CSF and (D, F) plasma HIV RNA were measured by RT-qPCR. Associations between frontal 
Plasma HIV RNA

















   
   




























   
   

























   
   






HIV+ r = 0.795, p = 0.011

















   
   






HIV+ r = 0.963, p = 0.002

















   
   





HIV+ r = 0.873, p = 0.002

















   
   























cortex HO-1 protein or RNA expression and plasma or CSF HIV RNA were analyzed by Pearson’s 
correlation with line of best fit by linear regression.  





Figure 2.3 Expression of the HO-2 isoform is higher in frontal white matter in PLWH than in 
HIV-negative individuals 
HO-2 protein was measured by Western blot. (A) Effect of HIV infection on HO-2 expression in 
individual brain regions was measured by Student’s unpaired t-test. (B) Effect of HIV infection on 
whole brain HO-2 expression was measured by Student’s paired t-test, where the mean expression 
of HO-2 in each region in HIV-negative individuals was compared to the mean expression of HO-2 
that region in in PLWH. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001  
 

















   
   




























   
   











Figure 2.4 Immunoproteasome expression is higher in multiple brain regions in PLWH than 
in HIV-negative individuals 
LMP7 (A-B), Pa28a (C-D), and B5 (E-F) protein expression were measured by Western blot. (A, 
C, E) Effect of HIV infection on proteasome subunit expression in individual brain regions was 
measured by Student’s unpaired t-test. (B, D, F) Effect of HIV infection on whole brain proteasome 
subunit expression was measured by Student’s paired t-test. *p<0.05, ** p<0.01, ***p<0.001, 
****p<0.0001  
 


















   
   































   
   


























   
   






























   
   


























   
   

























   
   












Figure 2.5 Type I IFN-stimulated gene expression is higher in multiple brain regions in PLWH 
than in HIV-negative individuals 
 (A-B) MX1 and (C-D) ISG15 RNA expression were measured by RT-qPCR. (A,C) Effect of HIV 
infection on type I IFN-stimulated gene expression in individual brain regions was measured by 
Student’s unpaired t-test. (B, D) Effect of HIV infection on whole brain IFN-stimulated gene 
expression was measured by Student’s paired t-test. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001 
 

















   
   























   
   































   
   
























   
   









Figure 2.6 Endothelial activation and adhesion marker expression is higher in multiple brain 
regions in PLWH than in HIV-negative individuals 
ICAM-1 (A-B), VCAM-1 (C-D), and PECAM-1 (E-F) protein expression were measured by Western 
blot. (A, C, E) Effect of HIV infection on endothelial adhesion molecule expression in individual 
brain regions was measured by Student’s unpaired t-test. (B, D, F) Effect of HIV infection on whole 
brain endothelial adhesion molecule expression was measured by Student’s paired t-test. *p<0.05, 
** p<0.01, ***p<0.001, ****p<0.0001 
 

















   
   


























   
   

























   
   





























   
   


























   
   




























   
   













Figure 2.7 Synaptic marker expression is similar in PLWH and HIV-negative individuals 
 (A-B) PSD95 and (C-D) synaptophysin protein expression were measured by Western blot. (a, c) 
Effect of HIV infection on synaptic marker expression in individual brain regions was measured by 
Student’s unpaired t-test. (B, D) Effect of HIV infection on synaptic marker expression was 
measured by Student’s paired t-test. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001  
 














































   
   

























   
   




























   
   












Figure 2.8 HO-1 (GT)n promoter genotype does not associate with HO-1 expression 
 (A) HO-1 protein and (B) RNA expression were measured by Western blot and RT-qPCR, 
respectively. PLWH were stratified by promoter genotype (orange circles: short/short [S/S]; blue 
squares: long/long [L/L]). (A, C) Effect of HO-1 (GT)n promoter genotype on HO-1 expression in 
individual brain regions was measured by Student’s unpaired t-test. (B, D) Effect of HO-1 (GT)n 
promoter genotype on whole brain HO-1 expression was measured by Student’s paired t-test. 
*p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001 
 
















   
   






















   
   




































   
   






























   
   










Figure 2.9 Hypothesized role for HO-1 in the development of HIV NCI 
Schematic depicting proposed relationships between inflammation and oxidative stress, HO-1, 
immunoproteasome, and NCI in PLWH. HIV infection increases inflammation and oxidative stress, 
which associates with HIV NCI. Inflammation and oxidative stress also stimulate 
immunoproteasome and HO-1 expression. HO-1 induction limits inflammation, oxidative stress, 
and may protect against HIV NCI. Immunoproteasome induction drives down HO-1, decrease of 




 HIV- HIV+ p-value 
Demographic Data, mean ± SD       
Number of Subjects 7 9  
Age at death (mean ± SD) 60 ± 15.7 51 ± 11.0 0.196 § 
Hours postmortem (mean ± SD) 18 ± 9.9 19 ± 8.0 0.850 § 
Sex, N (%)    
Male  5 (71%) 8 (89%) 0.37 † 
 Female 2 (29%) 1 (11%) 
Race, N (%)     
White 5 (71%) 6 (67%) 
0.84 † 
 Black 2 (29%) 3 (33%) 
Other/Unknown 0 (0%) 0 (0%) 
Ethnicity, N (%)     
Hispanic 0 (0%) 0 (0%)  
 Not Hispanic 7 (100%) 9 (100%) 
    
Disease Parameters, mean ± SD  ¶     
Log plasma HIV c/mL - 4.2 ± 1.5  
Log CSF HIV c/mL - 2.9 ± 0.7  
CD4+ lymphocytes/mm3 - 120 ± 148.2  
    
Neurocognitive Impairment, N (%)      
HIV-NCI  - 0 (0%) 
 
Neuropsychological Impairment- 
Other  - 4 (44%) 
Neurocognitive Normal  - 5 (56%) 
No Neurocognitive Data - 0 (0%) 
    
ART, N (%)        
ART-experienced - 8 (89%) 
 ART-naïve - 0 (0%) 
Unknown ART - 1 (11%) 
Table 2.1 Demographic and clinical data for PLWH cohort 
Data are presented as mean ± standard deviation (SD) or as population percentages.  
Abbreviations: Cerebrospinal fluid (CSF), HIV-associated neurocognitive impairment (HIV NCI), 
antiretroviral therapy (ART). Statistical analyses: § Student’s t-test; † Chi-square Test.  
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Regions Analyzed Abbreviation 
Frontal Cortex FC 
Temporal Cortex TC 
Occipital Cortex OC 
Motor Cortex MC 
Sensory Cortex SC 
Anterior Cingulate Cortex ACC 
Posterior Cingulate Cortex PCC 
Amygdala AM 
Caudate Nucleus/Putamen CN 





Frontal White Matter FWM 
Spinal Cord SPC 
 





Primary Antibodies        
Antibody Type Source Catalog # Dilution 
b-tubulin Rabbit mAb Cell Signaling Technology 2128L 1:3000 
Proteasome subunit 






b5 Rabbit pAb Invitrogen PA1-977 1:1000 
GAPDH Mouse mAb Calbiochem CB1001 1:20000 
VCAM-1 Rabbit mAb Abcam ab134047 1:2000 
PECAM-1 Rabbit pAb Abcam ab28364 1:500 
ICAM-1 Rabbit mAb Abcam ab109361 1:1000 
PSD95 Mouse mAb EMD Millipore MAB1596 1:1000 
Synaptophysin Mouse mAb Abcam Ab8049 1:1000 
HO-2 Rabbit pAb Enzo Life Sciences SPA-897 1:1000 
HO-1 Rabbit pAb Enzo Life Sciences SPA-895 1:500 
HO-1 Rabbit pAb Enzo Life Sciences SPA-894 1:500 
Proteasome subunit 
Pa28a 




Table 2.3 Primary antibodies used for Western blot  




Secondary Antibodies       
Antibody Type Source Catalog # Dilution 
IRDye 680RD Goat anti-mouse IgG LI-COR Biosciences 926-68070 1:20,000 
IRDye 680RD Goat anti-rabbit IgG LI-COR Biosciences 926-68071 1:20,000 
IRDye 
800CW Goat anti-mouse IgG LI-COR Biosciences 926-32210 1:15,000 
IRDye 
800CW Goat anti-rabbit IgG LI-COR Biosciences 926-32211 1:15,000 
 





HO-1 protein vs. HO-1 RNA 
 HIV-negative PLWH 
Region Pearson r p-value Pearson r p-value 
FC 0.301 0.563 0.586 0.097 
TC 0.298 0.626 0.813 0.008 
OC 0.612 0.144 0.673 0.047 
MC 0.666 0.103 0.808 0.008 
SC 0.150 0.776 0.686 0.041 
ACC -0.009 0.985 0.667 0.050 
PCC 0.470 0.287 0.675 0.046 
AM 0.725 0.065 0.537 0.136 
CN 0.240 0.605 0.577 0.104 
GP -0.067 0.887 0.633 0.068 
PN 0.192 0.679 0.534 0.139 
MB 0.146 0.754 0.167 0.668 
MED 0.162 0.728 0.525 0.182 
CB 0.273 0.601 0.132 0.736 
FWM 0.287 0.533 0.683 0.043 
SPC 0.800 0.104 0.731 0.062 
 
Table 2.5 HO-1 protein associates positively with HO-1 RNA in PLWH 
Correlations between HO-1 RNA and protein were analyzed by Pearson’s correlation. Bold and 




 HO-1 RNA vs. CSF HIV RNA 
HO-1 protein vs. 
CSF HIV RNA 
HO-1 RNA vs. 
plasma HIV RNA 
HO-1 protein vs. 
plasma HIV RNA 















FC 0.941 0.005 0.963 0.002 0.873 0.002 0.795 0.011 
TC 0.936 0.006 0.957 0.003 0.903 0.001 0.930 0.000 
OC 0.766 0.076 0.843 0.035 0.822 0.007 0.670 0.048 
MC 0.955 0.003 0.910 0.012 0.942 0.000 0.875 0.002 
SC 0.969 0.001 0.764 0.077 0.876 0.002 0.759 0.018 
ACC 0.988 0.000 0.935 0.006 0.866 0.003 0.634 0.067 
PCC 0.782 0.066 0.791 0.061 0.741 0.022 0.709 0.033 
AM 0.812 0.050 0.799 0.056 0.745 0.021 0.532 0.140 
CN 0.540 0.269 0.779 0.068 0.650 0.058 0.506 0.164 
GP 0.986 0.000 0.808 0.052 0.870 0.002 0.428 0.251 
PN 0.792 0.061 0.770 0.073 0.730 0.026 0.770 0.015 
MB 0.276 0.596 0.421 0.405 0.317 0.407 0.355 0.348 
MED 0.804 0.101 0.845 0.071 0.750 0.032 0.663 0.073 
CB 0.975 0.001 0.261 0.617 0.740 0.023 0.236 0.542 
FWM 0.596 0.212 0.640 0.171 0.390 0.299 0.499 0.171 
SPC 0.824 0.176 0.723 0.168 0.760 0.048 0.494 0.214 
 
Table 2.6 Brain HO-1 RNA and protein associate with CSF and plasma HIV RNA in PLWH 
Correlations between HO-1 RNA or protein and CSF or HIV RNA in individual regions were 






HO-1 RNA vs. LMP7 protein HO-1 protein vs. LMP7 protein 
 HIV-negative PLWH HIV-negative PLWH 







FC -0.114 0.830 0.288 0.452 0.360 0.428 0.676 0.046 
TC -0.229 0.711 0.202 0.602 0.219 0.637 0.474 0.198 
OC 0.686 0.089 0.295 0.441 0.374 0.408 0.213 0.582 
MC 0.754 0.050 0.003 0.994 0.190 0.683 -0.094 0.810 
SC 0.011 0.984 0.105 0.789 0.111 0.812 -0.093 0.812 
ACC 0.688 0.088 0.378 0.317 0.129 0.783 0.202 0.602 
PCC 0.109 0.8163 0.065 0.8681 0.400 0.3745 0.289 0.4506 
AM 0.559 0.192 0.009 0.982 0.827 0.022 -0.134 0.732 
CN 0.180 0.699 0.023 0.953 0.065 0.890 0.068 0.863 
GP 0.056 0.905 0.195 0.615 -0.665 0.104 0.372 0.324 
PN -0.265 0.566 0.552 0.124 0.092 0.844 0.347 0.360 
MB -0.173 0.711 0.014 0.972 0.623 0.135 0.151 0.698 
MED 0.095 0.839 0.449 0.264 0.635 0.125 0.339 0.412 
CB 0.151 0.775 -0.446 0.229 0.169 0.718 0.232 0.549 
FWM -0.224 0.629 -0.239 0.535 0.568 0.183 -0.247 0.521 
SPC 0.147 0.814 0.885 0.008 0.558 0.193 0.627 0.096 
 
Table 2.7 Associations between brain HO-1 and immunoproteasome subunit LMP7 in 
PLWH and HIV-negative individuals 
Correlations between HO-1 RNA or protein and LMP7 in individual regions were analyzed by 





	 ISG15 RNA vs. HO-1 RNA 
ISG15 RNA vs. 
HO-1 protein 
MX1 RNA vs. HO-1 
RNA 
MX1 RNA vs. 
HO-1 protein 













FC 0.497 0.173 0.311 0.415 0.510 0.161 -0.239 0.535 
TC 0.712 0.032 0.605 0.085 0.706 0.034 0.435 0.241 
OC 0.588 0.096 0.559 0.118 0.670 0.048 0.412 0.270 
MC 0.589 0.096 0.588 0.096 0.355 0.348 0.347 0.361 
SC 0.615 0.078 0.213 0.583 0.350 0.355 -0.044 0.910 
ACC 0.755 0.019 0.725 0.027 0.736 0.024 0.472 0.199 
PCC 0.714 0.031 0.613 0.080 0.630 0.069 0.480 0.191 
AM 0.634 0.067 0.724 0.027 0.741 0.022 0.466 0.207 
CN 0.204 0.599 0.556 0.120 0.481 0.190 0.590 0.094 
GP 0.540 0.134 0.655 0.055 0.403 0.282 0.505 0.166 
PN 0.247 0.522 0.203 0.600 0.107 0.783 -0.153 0.695 
MB 0.634 0.067 -0.297 0.438 0.563 0.115 -0.308 0.420 
MED 0.489 0.219 0.191 0.650 0.000 >0.999 -0.516 0.191 
CB 0.559 0.117 -0.216 0.577 0.750 0.020 0.128 0.744 
FWM 0.738 0.023 0.802 0.009 0.768 0.016 0.650 0.058 
SPC 0.680 0.093 0.839 0.018 0.798 0.031 0.583 0.170 
 
Table 2.8 Associations between brain HO-1 and type I IFN-stimulated genes in PLWH 
Correlations between HO-1 RNA or protein and ISG15 or MX1 RNA in individual regions were 





 ISG15 RNA vs. HO-1 RNA 
ISG15 RNA vs. 
HO-1 protein 
MX1 RNA vs. 
HO-1 RNA 
MX1 RNA vs. 
HO-1 protein 















FC -0.100 0.850 -0.276 0.597 -0.446 0.376 -0.680 0.138 
TC -0.097 0.876 -0.602 0.282 -0.189 0.761 -0.920 0.027 
OC 0.068 0.884 -0.412 0.358 -0.185 0.691 -0.567 0.184 
MC 0.165 0.724 -0.110 0.815 -0.100 0.831 -0.370 0.414 
SC 0.099 0.852 -0.293 0.573 0.214 0.684 -0.478 0.337 
ACC 0.077 0.871 -0.584 0.169 -0.292 0.526 -0.617 0.140 
PCC -0.163 0.727 -0.061 0.896 -0.264 0.567 -0.229 0.6218 
AM 0.102 0.828 -0.130 0.781 0.082 0.862 -0.118 0.801 
CN -0.630 0.130 -0.025 0.958 -0.279 0.544 0.390 0.387 
GP -0.569 0.182 -0.374 0.408 -0.773 0.042 -0.110 0.814 
PN -0.385 0.394 0.110 0.815 -0.383 0.396 -0.222 0.632 
MB -0.427 0.339 -0.065 0.889 -0.550 0.201 0.305 0.507 
MED 0.558 0.193 0.210 0.651 0.654 0.111 0.350 0.441 
CB -0.484 0.331 -0.029 0.956 -0.732 0.098 -0.729 0.101 
FWM -0.079 0.867 -0.346 0.447 -0.553 0.198 -0.632 0.128 
SPC -0.248 0.687 -0.686 0.201 -0.241 0.696 -0.708 0.181 
 
Table 2.9 Associations between brain HO-1 and type I IFN-stimulated genes in HIV-
negative individuals 
Correlations between HO-1 RNA or protein and ISG15 or MX1 RNA in individual regions were 



















protein vs. HO-1 
RNA 
PECAM-1 
protein vs. HO-1 
protein 























FC 0.219 0.571 0.407 0.277 0.320 0.401 0.847 0.004 0.738 0.023 0.258 0.503 
TC 0.049 0.900 0.180 0.644 0.385 0.306 0.827 0.006 0.870 0.002 0.752 0.020 
OC -0.324 0.395 0.141 0.719 0.285 0.458 0.039 0.921 0.768 0.016 0.888 0.001 
MC 0.279 0.468 0.114 0.771 0.611 0.081 0.626 0.071 0.753 0.019 0.513 0.158 
SC 0.435 0.242 0.132 0.735 0.497 0.173 0.535 0.138 0.777 0.014 0.175 0.652 
ACC 0.199 0.607 0.294 0.443 0.556 0.120 0.906 0.001 0.751 0.020 0.569 0.110 
PCC -0.093 0.812 0.134 0.731 0.308 0.420 0.364 0.336 0.544 0.131 0.782 0.013 
AM -0.051 0.895 -0.275 0.474 0.807 0.009 0.439 0.238 0.571 0.108 0.659 0.054 
CN -0.190 0.625 -0.089 0.821 0.780 0.013 0.407 0.277 0.708 0.033 0.461 0.212 
GP 0.161 0.679 0.125 0.748 0.615 0.078 0.619 0.076 0.623 0.073 0.679 0.044 
PN -0.215 0.578 0.186 0.633 0.207 0.592 0.748 0.021 0.768 0.016 0.551 0.125 
MB -0.039 0.920 0.293 0.481 0.243 0.528 0.778 0.023 0.299 0.435 0.562 0.147 
MED -0.160 0.706 0.332 0.422 0.556 0.152 0.686 0.060 0.493 0.214 0.364 0.375 
CB -0.401 0.285 -0.203 0.601 0.253 0.512 -0.065 0.869 0.497 0.174 -0.004 0.992 
FWM 0.399 0.288 0.094 0.810 0.364 0.336 0.504 0.167 0.377 0.317 0.226 0.558 
SPC 0.483 0.273 0.352 0.393 0.315 0.491 0.859 0.006 0.719 0.069 0.532 0.175 
 
Table 2.10 Associations between brain HO-1 and endothelial adhesion molecules in PLWH 
Correlations between HO-1 RNA or protein and ICAM-1, VCAM-1, or PECAM-1 protein in individual 













vs. HO-1 protein 
PECAM-1 
protein vs. HO-1 
RNA 
PECAM-1 
protein vs. HO-1 
protein 























FC -0.650 0.163 0.117 0.803 -0.166 0.753 0.420 0.349 -0.511 0.301 0.609 0.147 
TC 0.642 0.243 0.155 0.741 -0.249 0.687 0.464 0.294 0.284 0.643 0.511 0.242 
OC 0.625 0.133 0.443 0.319 -0.308 0.501 0.265 0.566 0.297 0.518 0.292 0.526 
MC 0.293 0.523 0.013 0.978 -0.597 0.157 -0.018 0.970 0.551 0.200 0.172 0.713 
SC -0.776 0.070 -0.317 0.489 -0.774 0.071 0.294 0.522 -0.451 0.370 -0.230 0.619 
ACC 0.200 0.668 0.629 0.130 -0.477 0.279 0.674 0.097 -0.129 0.784 0.363 0.424 
PCC -0.283 0.538 -0.221 0.634 -0.183 0.695 -0.035 0.941 0.401 0.373 0.752 0.051 
AM -0.083 0.860 0.255 0.581 -0.311 0.498 0.439 0.238 -0.240 0.604 0.184 0.694 
CN 0.418 0.351 0.543 0.208 0.312 0.496 0.443 0.319 0.161 0.730 0.017 0.972 
GP -0.391 0.386 0.024 0.960 -0.350 0.441 -0.326 0.476 0.105 0.824 -0.084 0.857 
PN 0.230 0.621 0.961 0.001 0.145 0.756 -0.466 0.292 -0.100 0.832 0.784 0.037 
MB -0.030 0.948 0.104 0.824 -0.609 0.147 0.379 0.402 -0.096 0.838 0.129 0.783 
MED -0.079 0.866 0.426 0.341 -0.062 0.896 0.199 0.669 -0.608 0.148 0.190 0.684 
CB 0.100 0.851 0.004 0.993 -0.780 0.067 0.400 0.374 -0.418 0.409 0.468 0.290 
FWM -0.408 0.364 0.300 0.513 -0.667 0.102 0.389 0.388 -0.586 0.167 0.565 0.186 
SPC 0.913 0.030 0.238 0.607 -0.488 0.404 0.000 0.999 0.162 0.795 0.368 0.417 
 
Table 2.11 Associations between brain HO-1 and endothelial adhesion molecules in HIV-
negative individuals 
Correlations between HO-1 RNA or protein and ICAM-1, VCAM-1, or PECAM-1 protein in individual 





		 PSD95 protein vs. HO-1 RNA 
PSD95 protein 
vs. HO-1 protein 
Synaptophysin 
protein vs. HO-1 
RNA 
Synaptophysin 
protein vs. HO-1 
protein 















FC 0.168 0.666 -0.063 0.872 -0.297 0.437 0.309 0.419 
TC 0.396 0.291 0.171 0.660 -0.073 0.853 0.097 0.804 
OC 0.647 0.060 0.666 0.050 -0.258 0.504 -0.526 0.145 
MC 0.125 0.749 0.123 0.753 -0.184 0.635 -0.103 0.792 
SC 0.433 0.244 -0.011 0.979 -0.293 0.445 -0.447 0.228 
ACC 0.508 0.162 0.597 0.089 -0.222 0.566 -0.057 0.883 
PCC 0.476 0.195 0.646 0.060 -0.279 0.467 -0.110 0.7774 
AM 0.548 0.127 0.595 0.091 0.093 0.812 0.191 0.623 
CN 0.379 0.315 0.686 0.041 0.254 0.509 0.222 0.566 
GP 0.531 0.141 0.249 0.519 0.045 0.908 0.415 0.267 
PN 0.617 0.077 0.185 0.634 0.057 0.884 -0.119 0.761 
MB 0.421 0.260 0.468 0.243 0.561 0.116 0.323 0.435 
MED 0.536 0.171 0.221 0.598 0.077 0.855 0.023 0.957 
CB 0.292 0.445 -0.169 0.665 -0.545 0.129 0.040 0.919 
FWM -0.341 0.370 -0.466 0.206 -0.242 0.530 -0.571 0.108 
SPC 0.527 0.224 0.438 0.278 -0.647 0.116 -0.532 0.175 
 
Table 2.12 Associations between brain HO-1 and synaptic markers in PLWH 
Correlations between HO-1 RNA or protein and PSD95 or synaptophysin protein in individual 





 PSD95 protein vs. HO-1 RNA 
PSD95 protein vs. 
HO-1 protein 
Synaptophysin 
protein vs. HO-1 
RNA 
Synaptophysin 
protein vs. HO-1 
protein 















FC -0.184 0.727 0.003 0.995 0.215 0.682 0.791 0.034 
TC -0.431 0.469 0.546 0.205 -0.295 0.630 0.836 0.019 
OC 0.717 0.070 0.753 0.051 0.057 0.903 0.381 0.399 
MC 0.025 0.958 0.037 0.937 0.078 0.867 0.065 0.889 
SC -0.490 0.324 -0.209 0.653 0.489 0.325 0.130 0.781 
ACC -0.038 0.936 -0.100 0.831 0.205 0.660 -0.266 0.564 
PCC 0.213 0.647 -0.149 0.749 -0.140 0.766 0.458 0.302 
AM 0.286 0.534 0.056 0.905 0.286 0.535 0.770 0.043 
CN -0.057 0.903 -0.493 0.261 -0.400 0.374 -0.700 0.080 
GP -0.019 0.969 0.514 0.238 -0.307 0.503 0.589 0.164 
PN 0.666 0.103 0.093 0.843 0.528 0.223 0.469 0.289 
MB -0.055 0.907 0.300 0.513 -0.170 0.716 0.503 0.250 
MED -0.552 0.199 0.537 0.214 -0.260 0.573 0.797 0.032 
CB 0.339 0.511 -0.423 0.344 -0.409 0.421 0.360 0.428 
FWM 0.133 0.776 0.756 0.049 0.178 0.702 0.639 0.123 
SPC -0.647 0.238 -0.246 0.595 -0.829 0.083 0.248 0.592 
 
Table 2.13 Associations between brain HO-1 and synaptic markers in HIV-negative 
individuals 
Correlations between HO-1 RNA or protein and PSD95 or synaptophysin protein in individual 
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Blood-brain barrier (BBB) disruption is well-known in HIV infection and may contribute to 
development of HIV-associated neurocognitive impairment (HIV NCI). Host antioxidant response 
enzyme HO-1 has been shown to support key functions of endothelial cells, which comprise the 
main structural component of the BBB, including tight junction permeability and transendothelial 
migration (116, 216). We have previously demonstrated that reduced HO-1 expression in prefrontal 
cortex associates with HIV NCI, and that HO-1 expression associates with expression of endothelial 
adhesion molecules throughout the brain in PLWH (Table 2.10) (36). Whether reduction of 
endothelial HO-1 contributes to BBB disruption in HIV infection is unknown. Similarly, the potential 
of induction of HO-1 as a therapeutic strategy to support BBB function in HIV infection is unclear. 
Here, we used two human brain endothelial cell models (hCMEC/D3 cell line (217) and primary 
human brain microvascular endothelial cells [HBMECs]) to interrogate the role for HO-1 expression 
in tight junction permeability and transendothelial migration. We modulated HO-1 expression 
pharmacologically and genetically in each model. HO-1 induction and knockdown, however, did 
not affect tight junction permeability or expression of adhesion molecules in response to pro-
inflammatory stimuli. We successfully modeled chemotactic transendothelial migration of 
monocytes in both hCMEC/D3 cells and HBMECs. Our results indicate that each of these cell types 
can be utilized to determine HO-1-specific effects on BBB functions. Further development of 
experimental paradigms modeling inflammatory stimuli relevant to HIV infection is required to better 






Despite the introduction of highly active combination antiretroviral therapy (ART), HIV-associated 
neurocognitive impairment (HIV NCI) affecting activities of daily functioning persists in ~15% of 
persons living with HIV (PLWH) (9). While transient increases in HIV RNA in the CSF, known as 
“blips,” occur in up to 21% of PLWH on ART(153, 218), there is not a clear relationship between 
systemic or CNS replication and HIV NCI in individuals on ART(219), suggesting distinct or 
additional factors contributing to HIV NCI. Disruption to the blood-brain barrier (BBB), evidenced in 
vivo by increased neurofilament light chain protein (NFL) in CSF, increased CSF/plasma albumin 
ratio, and contrast enhanced MRI in infected individuals, is well-known in HIV infection (29, 220-
225). Brain microvascular endothelial cells (HBMECs) are the primary structural component of the 
BBB. HBMECs are supported by smooth-muscle like pericytes embedded within the basement 
membrane and astrocyte endfeet that secrete supportive and regulatory factors; these cells are 
also considered components of the BBB (32, 33). The BBB possesses selective tight junctions 
(TJs), high transendothelial electrical resistance (TEER), and tight regulation of adhesion and 
transmigration of leukocytes, protecting the CNS from potentially harmful elements in the 
circulation(30, 32, 34, 226, 227). Increased BBB permeability and infiltration of activated and/or 
infected leukocytes into the CNS perpetuates inflammation and oxidative stress in the CNS 
compartment that likely contributes to neurocognitive impairment(31, 56, 154, 228).  
 
A critical host response to inflammation and oxidative stress is the coordinated induction of genes 
regulated through the antioxidant response element (ARE) pathway (105). An array of genes 
encoding detoxifying and cytoprotective effector proteins contain this common promoter element 
(the ARE), and are induced in response to changes in cellular redox status (71, 72). A growing 
body of work supports a protective role for a particular ARE effector protein, heme oxygenase-1 
(HO-1), against HIV NCI. HO-1 is a highly inducible, cytoprotective, and has potent anti-
inflammatory and antioxidant effects (92, 229). HO-1 is critical to the host antioxidant response, 
catalyzing the rate-limiting first step of heme metabolism, cleaving heme to biliverdin, ferrous iron, 
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and carbon monoxide (92). HO-1 is induced by its substrate heme, as well as many other cellular 
stressors including microbial products and pro-inflammatory cytokines (92). HO-1 transcription is 
partially regulated by a (GT)n dinucleotide repeat polymorphism in its promoter region that 
modulates basal transcription and inducibility of HO-1 in response to stimuli (90). Shorter repeat 
length allele genotypes associate with better outcomes in numerous systemic and CNS disease 
states, as well as systemic HIV (89, 107, 113). We recently found that shorter repeat length alleles 
also associate with reduced risk for HIV NCI and HIV encephalitis (114, 115). Furthermore, HO-1 
protein expression is reduced in dorsolateral prefrontal cortex of PLWH with HIV NCI, and this 
decreased HO-1 expression associates with increased neuroinflammation and HIV NCI. HIV-
induced glial loss of HO-1 expression associates with the release of neurotoxic levels of glutamate 
(36, 166). Most recently, we have shown that HO-1 associates with expression of endothelial 
adhesion molecules throughout the brain in PLWH (Chapter 2).  
 
In the brain, HO-1 is expressed in glial cells (astrocytes, microglia) as well as the highly specialized 
brain microvascular endothelial cells that comprise the primary structural component of the BBB. 
Endothelial HO-1 expression has been shown to have protective effects in several pathologic 
conditions, including cerebral ischemia and oxygen toxicity (230, 231). Additionally, HO-1 has been 
found to modulate expression of inflammatory cytokine-induced adhesion molecules in aortic 
endothelial cells (232). The contribution of HO-1 to the maintenance of barrier integrity and function 
in endothelial cells suggests that modulation of HO-1 expression might affect BBB functions 
relevant to the development of HIV NCI. We hypothesized that modulation of endothelial HO-1 
expression affects the BBB’s functional response to inflammation through TJ integrity and leukocyte 
adhesion and transmigration. 
 
In order to interrogate the role for endothelial HO-1 expression in BBB function, we employed two 
in vitro models: a well-established endothelial cell line (hCMEC/D3 cells) and primary human brain 
microvascular endothelial cells (HBMECs). The hCMEC/D3 line is derived from culture of primary 
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adult temporal lobe microvessels, immortalized by lentiviral transduction of hTERT and SV40 large 
T antigen (217). In their initial development, hCMEC/D3s were shown to express TJ markers 
claudin-5 and ZO-1 and adhesion molecule PECAM-1 (217). However, hCMEC/D3 monolayer 
TEER is not as high as those observed in vivo or using primary endothelial cells or induced 
pluripotent stem cell-derived models, representing a limitation of this model (233). BBB models 
employed here consisted of endothelial cells seeded onto transwell inserts, mimicking the HBMEC 
barrier between plasma and CNS. Primary HBMEC models included human fetal astrocytes, 
adding another BBB component to the model. We lacked inclusion of pericytes and perivascular 
macrophages/microglia. In each model, we i) determined basal HO-1 expression; ii) defined the 
response to pharmacologic HO-1 inducers; and iii) specifically modulated HO-1 expression using 
siRNAs. Finally, we used each cell type to model critical BBB functions: monolayer impermeability, 
and transendothelial migration of monocytes. Our data suggest that hCMEC/D3 cells, HO-1 
induction may ameliorate TNFa-induced monolayer permeability. Using HBMECs, we confirmed 
that human primary endothelial-astrocyte co-cultures can reliably model monocyte transmigration 
in response to CCL2, and that HO-1 can be genetically manipulated within this model.  
 
3.3 Materials and Methods 
hCMEC/D3 cell culture 
hCMEC/D3 cells (217) were obtained courtesy of Dr. Jorge Alvarez (University of Pennsylvania). 
Cells were cultured in endothelial cell media (ECM): EBM-2 basal media (Lonza) with 5% fetal 
bovine serum, 1.4uM hydrocortisone (Sigma), 5ug/mL ascorbic acid (Sigma), 1% Chemically 
Defined Lipid Concentrate (Gibco), 10mM HEPES (Sigma), 200ng/mL Fibroblast Growth Factor-
basic (Millipore). Cells were passaged every 4-6 days to T25 flasks coated with 1:500 rat tail 





Human brain microvascular endothelial cell culture 
Human brain microvascular endothelial cells (HBMEC) (P1-P3) were obtained from ScienCell (cat. 
#1000) and cultured in M199C media: Media 199 (Gibco) with 200mM L-glutamine, 50mg/mL 
ascorbic acid (Sigma), 1% pen/strep, 25mg/mL heparin (Sigma), 3mg/mL Sigma Growth Factor 
(Sigma), 9mg/mL bovine brain extract (Clonetics), 5% human serum type AB (Corning), 20% 
newborn calf serum (Gibco). Cells were subcultured every 3-6 days to 100mm dishes coated with 
0.2% laboratory grade gelatin (Fisher). Cells were maintained at 37°C and 5% CO2. 
 
Human fetal astrocyte cell culture 
Primary human fetal astrocyte cultures were prepared and frozen down by the Basic Science Core 
I of the Comprehensive NeuroAIDS Center (CNAC) at Temple University School of Medicine. Fetal 
brain tissues (gestational age 16-18 weeks) obtained from elective abortion procedures were 
washed in Hank’s balanced salt solution (HBSS), meninges and blood vessels were removed, and 
tissues were mechanically disrupted then digested with 0.25% trypsin (Life Technologies) and 
10U/mL DNASE I (Sigma-Aldrich). Single cell suspensions were plated in mixed glial growth media 
(Dulbecco’s modified eagle medium/Ham’s F-12 nutrient mixture with HEPES (DMEM/F-12, Gibco) 
supplemented with 10% FBS (HyClone), 50ug/mL Gentamicin (Gibco), 5ug/mL Fungizone (Gibco), 
2mM L-glutamine (Gibco), and 10ug/mL Insulin (Sigma-Aldrich)) and maintained under 10% CO2 
for 5 days. To enrich for astrocytes, the mixed glial cell cultures were shaken at 200rpm for 14-18 
hours, medium containing detached cells was removed, and the remaining adherent monolayers 
of astrocytes were fed with astrocyte growth media (DMEM/F-12 supplemented with 15% FBS, 
50ug/mL Gentamicin, 5ug/mL Fungizone, 2mM L-glutamine, and 10ug/mL insulin) and maintained 






hCMEC/D3 cells were transfected at 80% confluency with 20nM Silencer Select siRNAs (Ambion) 
using Lipofectamine RNAiMax (Invitrogen) for a transfection period of 24-96 hours. Lipofectamine 
and siRNAs were incubated for 5 minutes in OptiMEM (Invitrogen) at room temperature prior to 
addition to cells. Control conditions included Lipofectamine alone and transfection with Silencer 
negative control siRNA targeting a scramble sequence (#4390846). HBMECs were transfected with 
20nM Silencer Select siRNAs (Ambion) using Amaxa Nucleofector Kit V (Lonza) according to 
manufacturer’s instructions and as described, using program T-23 (234). Controls included cells 
not electroporated, cells electroporated without any siRNA, and electroporation with Silencer 
negative control siRNA. siRNA targeting HO-1 (s6673) was used to knock down HO-1, while siRNA 
targeting BACH1 (s1859), a transcriptional repressor of HO-1, was used to induce HO-1 expression 
(36, 215). 
 
Protein extraction and Western blot analysis 
Protein lysates from hCMEC/D3 cell cultures were prepared in radioimmunoprecipitation assay 
(RIPA) lysis buffer (Amresco) supplemented with Complete Protease Inhibitor Cocktail (Roche 
Applied Science). Protein concentration was quantified using the Detergent Compatible (DC) 
protein assay (BioRad). Proteins were resolved by SDS-PAGE and transferred to polyvinylidene 
fluoride (PVDF) membranes. Membranes were incubated with primary antibody overnight at 4°C. 
For infrared fluorescent detection of protein expression, membranes were incubated with IRDye-
conjugated secondary antibody for one hour at room temperature and scanned with the Odyssey 
CLx Infrared Imagine System (LI-COR Biosciences). Background-corrected signal intensity of 
protein bands was measured using Image Studio Lite software (LI-COR Biosciences). Protein 
expression was normalized to GAPDH or b-tubulin and fold change was calculated relative to in-





Permeability of hCMEC/D3 or HBMEC monolayers on PET transwell inserts (Falcon) was assessed 
by tracer molecule (70 kDa FITC-dextran) exclusion as previously described (217, 235). In 
experiments only testing permeability, 0.4um-pore inserts were used, while 3.0um inserts were 
used in experiments also testing monocyte transmigration. FITC-dextran in respective endothelial 
cell media (2ng/mL) was added to the upper chamber of inserts. Every 5 minutes for 30 minutes, 
10uL of media from the lower chamber was sampled and transferred to individual wells of 96-well 
plates. Fluorescence intensity of these samples was measured using a flour metric plate reader. 
Permeability is represented as Arbitrary Fluorescent Units measured at 30 minutes or permeability 
coefficient (Pe). The permeability coefficient was calculated as follows: Pe = PS/s, where PS is the 
permeability surface area of the endothelial monolayer and s is the surface area of the filter. PS is 
calculated by 1/PS = 1/me – 1/mf, where me and mf are the slopes of the curves corresponding to 
endothelial cells on filters and to filters only, respectively, with me and mf calculated by plotting the 
cleared volume against time. Cleared volume was calculated by (AUa-AUb)/Fi, where AUa is the 
total fluorescence (arbitrary units) in the basal compartment, AUb is the background fluorescence 
and Fi is the fluorescence of the initial solution (AU/mL) (235). 
 
Monocyte transmigration assay 
Peripheral blood mononuclear cells (PMBC) were isolated from volunteer donors by Ficoll density 
gradient centrifugation, and monocytes were isolated by adherence to gelatin-coated flasks (167). 
Enriched monocytes were added to the upper chamber of 3.0um transwell inserts (Falcon) with 
hCMEC/D3 or HBMEC monolayers and CCL2 (100-400ng/mL), which is known to enhance 
leukocyte transmigration (167, 236), was added concurrently to the lower chamber or both the 
upper and lower chambers. Monocytes were allowed to migrate for 24h. (Fig. 3.1A-B). Permeability 
assays were done in each condition before and after migration in order to ensure monolayer 
integrity. Monocyte transmigration was determined by counting cells in 5 10x fields per well in each 
of three technical replicate wells. Relative transmigration is represented as fold change in average 




Human BBB model 
HBMECs and primary human fetal astrocytes were cultured on opposite surfaces of 0.2% gelatin-
coated 3.0um-pore polyethylene terephthalate (PET) inserts (Falcon) in M199C+ media to model 
the BBB as previously described (Fig. 3.1B) (237). Astrocytes were seeded to the underside of 
inserts and allowed to adhere for 4 hours. Inserts were inverted and placed into appropriate plates, 
after which HBMECs were seeded to the upper surface. Co-cultures were incubated at 37°C and 
5% CO2 for 48 hours to obtain confluent endothelial monolayers. Co-cultures were then transferred 
to low-serum M199C media (M199 with 10% newborn calf serum and endothelial cell growth 
factors) for 24 hours before permeability and monocyte transmigration assays. Impermeability of 




All quantifications are expressed as mean ± standard error of the mean (SEM). Protein expression 
data were log transformed. Statistical comparisons of three or more groups were made by one-way 
ANOVA with Holm-Sidak post hoc test for multiple comparisons. Statistical comparisons 
determining effects of more than one independent variable were made by two-way ANOVA with 
Holm-Sidak post hoc test for multiple comparisons. All statistical analyses were performed using 




HO-1 responds predictably to pharmacologic manipulation in hCMEC/D3 cells 
We first determined whether we could predictably and reliably manipulate HO-1 expression in 
hCMEC/D3 cells using small molecules and cytokines known to induce HO-1 in other models: 
cobalt protoporphyrin (CoPP), dimethyl fumarate (DMF) and monomethyl fumarate (MMF) (Fig. 
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1.1). CoPP robustly induces HO-1 by both destabilizing BACH1 and stabilizing Nrf2, effectively 
deprepressing HO-1 transcription and enhancing it simultaneously (117). As expected, 24-hour 
treatment with 10uM CoPP robustly induced HO-1 expression (Fig. 3.2A-B). We next tested DMF 
and MMF, which induce HO-1 expression in monocyte-derived macrophages (MDM) and other cell 
types via electrophilic interactions with Keap1 (167, 238, 239). Both DMF and MMF treatment 
increased HO-1 expression in hCMEC/D3 cells, but with different kinetics (Fig. 3.2C-D). Treatment 
with 10uM DMF increased HO-1 expression to about four-fold when compared to untreated 
hCMEC/D3 cells, with peak expression occurring at 8 hours post-treatment. Treatment with 10uM 
MMF increased HO-1 expression to a similar magnitude, but with peak expression occurring at 24 
hours post-treatment. HO-1 expression at 48 hours post-treatment was similar with DMF and MMF 
treatment. Finally, we treated hCMEC/D3 cells with interferon-beta (IFNβ), which has been reported 
to support BBB function in MS studies (240), to determine its effect on HO-1 expression. Using a 
dose-response approach over the course of 6 days, we found modest increases in HO-1 expression 
with 0.1, 0.5, and 1ng/mL IFNβ treatment at 24 hours post-treatment (Fig. 3.2E-F). There was no 
difference in HO-1 expression between untreated cells and those exposed to any dose of IFNβ at 
4 or 6 days post-treatment. 
 
hCMEC/D3 cell blood-brain barrier model recapitulates cytokine-induced monocyte chemotaxis, 
but not barrier permeability  
With confirmation that we could observe and predictably manipulate HO-1 expression in 
hCMEC/D3 cells with known inducers, we next sought to use these cells to model the BBB using a 
transwell system. Based on previous reports, we hypothesized that hCMEC/D3 barrier permeability 
would increase in response to pro-inflammatory cytokines TNFα and IFNγ	(241), and that monocyte 
transmigration across the hCMEC/D3 monolayer would increase in response to monocyte 
chemoattractant protein 1 (CCL2)	 (237). We seeded hCMEC/D3 cells onto polyethylene 
terephthalate (PET) membrane inserts, and determined monolayer integrity by measuring 
permeation of 70kDa FITC-tagged dextran from the upper chamber to the lower chamber over time 
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(30 minutes). Permeability of the hCMEC/D3 monolayer to FITC-dextran progressively decreased 
over time after plating, reaching equilibrium between 6 to 8 days, and thus monolayers were 
assayed at least 6 days after plating in subsequent experiments (Fig. 3.3A). Pore size (0.4um or 
3.0 um) did not influence monolayer permeability, but serum content of the media did, suggesting 
that we had achieved a functional monolayer that would respond to soluble factors in media (Fig. 
3.3B). We next tested the monolayer’s response to pro-inflammatory cytokine treatment, with the 
hypothesis that exposure to IFNγ and TNFα would increase permeability as previously reported 
(241). hCMEC/D3 cells seeded to 0.4um-pore transwell inserts were transferred to serum-free 
media 24h prior to treatment. We exposed the monolayers to TNFα or IFNγ for 24h, after which we 
tested their permeability using 70kDa FITC-dextran. Contrary to our expectations, treatment with 
5-10ng/mL TNFα did not significantly increase monolayer permeability (Fig. 3.3C). Because 
hydrocortisone pre-treatment can prevent increased permeability of hCMEC/D3 cells in response 
to TNFα (242), we repeated this experiment using serum- and hydrocortisone-free media. Still, 
TNFα treatment did not increase monolayer permeability (Fig. 3.3C). Similarly, we did not find any 
significant increase in permeability when we treated hCMEC/D3 monolayers with 5-10ng/mL IFNγ 
(Fig. 3.3D). 
 
In addition to permeability, we aimed to use hCMEC/D3 cells to model transendothelial migration 
of lymphocytes. To do this, we measured migration of primary human monocytes across 
hCMEC/D3 monolayers in response to CCL2. We established hCMEC/D3 monolayers on 3um-
pore transwell inserts using media suitable for co-culture with primary human monocytes (RPMI 
5% FBS), which we had previously determined not to negatively impact monolayer permeability 
(Fig. 3.2B). To ensure that any observed increase in chemotaxis was due to diapedisis and not 
structural breakdown of the barrier, we first determined whether exposure to CCL2 would impact 
monolayer permeability. hCMEC/D3 monolayer permeability to 70kDa FITC-dextran after 24h 
exposure to 200ng/mL CCL2 in either the lower chamber or both upper and lower chambers (to 
differentiate between chemotaxis and chemikinesis) was not different compared to vehicle-treated 
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or untreated monolayers (Fig. 3.3E). When we applied primary human monocytes to the upper 
chamber of the transwell system at the same time as CCL2 (Fig. 3.1A), we observed that a greater 
number of monocytes migrated to the lower chambers with CCL2 compared to those with vehicle 
in the lower chamber or CCL2 in the upper and lower chambers (Fig. 3.3F). These data suggested 
that we could successfully model monocyte chemotaxis across a monolayer of hCMEC/D3 cells in 
response to CCL2. 
 
Genetic manipulation of HO-1 may prevent inflammation-induced permeability in hCMEC/D3 cells 
To determine the role for HO-1 in barrier function in hCMEC/D3 cells, we genetically manipulated 
HO-1 expression using siRNAs and evaluated monolayer permeability in those conditions. Using 
Lipofectamine to deliver siRNAs specific to HO-1 and its transcriptional repressor BACH1 (36, 215), 
we observed significant knockdown and induction of HO-1 expression, respectively, that persisted 
from 24h to 96h-post transfection (Fig. 3.4A). We tested permeability of hCMEC/D3 monolayers to 
70kDa FITC-dextran 72h post-transfection, and observed a modest increase in permeability in 
monolayers treated with siRNA against HO-1, although this observation was not significant (Fig. 
3.4B). Finally, we tested whether knockdown or induction of HO-1 prior to exposure to TNFα would 
impact permeability of hCMEC/D3 monolayers using the timeline of transfection efficacy we had 
previously observed (Fig. 3.4A) (241). We transfected hCMEC/D3 cells with siRNAs against HO-1 
or BACH1 in our transwell system, then treated with 10ng/mL TNFα for 24h. Interestingly, we 
observed modest increases in permeability in TNFα-treated monolayers that had been transfected 
with scrambled-control siRNA or siRNA against HO-1 compared to untreated monolayers of the 
same siRNA condition, but not in monolayers transfected with siRNA against BACH1 (Fig. 3.4C). 
These results suggest that induction of HO-1 prior to exposure to TNFα may protect against 
inflammation-induced permeability in hCMEC/D3 cells. However, increased permeability with TNFα 
treatment was not observed in the untreated condition, and further investigation is required to 




Primary human brain microvascular endothelial cells express HO-1 in response to pharmacologic 
and genetic manipulation 
With confirmation that we could observe and manipulate HO-1 expression and model BBB 
functions (monolayer permeability and transendothelial migration) using hCMEC/D3 cells in a 
transwell system, we applied these techniques to a more biologically relevant co-culture model 
using all primary cells. Using primary human brain microvascular endothelial cells (HBMECs), we 
first determined whether these cells i) express HO-1 under basal conditions, and ii) increase HO-1 
expression in response to CoPP. Indeed, 10uM CoPP robustly induced HO-1 expression in 
HBMECs after 24h, while basal HO-1 expression was low difficult to resolve by Western blot (Fig. 
3.5A). We performed a dose response experiment and observed increased HO-1 expression in 
response to 10uM CoPP 12h post-treatment (Fig. 3.5B). HO-1 expression continued to increase 
24h and 48h post-treatment with 10uM CoPP. 1uM CoPP increased HO-1 expression 24h and 48h 
post-treatment albeit to a lower degree than 10uM CoPP, while 100nM CoPP was not sufficient to 
increase HO-1 expression in HBMECs. We next attempted to genetically manipulate HO-1 
expression in HBMECs with siRNAs, using the same Lipofectamine protocol we had used in 
hCMEC/D3 cells. However, Lipofectamine delivery of siRNAs was ineffective in HBMECs, 
regardless of siRNA concentration, plating density of cells, and well coating used (data not shown). 
Using electroporation for delivery instead, we successfully knocked down and increased HO-1 
expression using siRNAs against HO-1 and BACH1, respectively (Fig. 3.5C). 
 
Pro-inflammatory cytokines increase endothelial adhesion molecule expression in HBMECs 
We next sought to determine whether HO-1 knockdown or induction would impact inflammation-
driven adhesion and transendothelial migration in HBMECs. We first determined expression of 
endothelial adhesion molecules (VCAM-1, ICAM-1) in response to TNFα or IFNγ (Fig. 3.6A-D). 
Both VCAM-1 and ICAM-1 expression increased in a dose-dependent manner in response to 
TNFα, while only ICAM-1 expression increased in response to IFNγ (quantified in Fig. 3.6C-D). 
Next, we determined adhesion molecule expression in response to TNFα treatment in HBMECs 
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pre-transfected with siRNAs to manipulate HO-1 expression. siRNAs against either HO-1 or 
BACH1 were delivered to HBMECs by electroporation. After 24h, cells were exposed to 1 or 
10ng/mL TNFα for another 24h after which we measured HO-1, VCAM-1, and ICAM-1 expression 
(Fig. 3.6E-G). VCAM-1 and ICAM-1 expression were both increased in cells treated with TNFα 
compared to untreated controls, as expected. However, there was no difference in adhesion 
molecule induction between siRNA conditions. We confirmed HO-1 induction in cells electroporated 
with siRNA against BACH1, however, at 48h post-transfection (time of lysate collection), this effect 
was modest (Fig. 3.6E), and the level of HO-1 induction may not have been sufficient to prevent 
adhesion molecule expression in response to TNFα. 
 
HBMEC tri-culture blood-brain barrier model recapitulates cytokine-induced transendothelial 
migration of monocytes 
Finally, we modeled transendothelial migration in a transwell system exclusively using primary 
human cells (Fig. 3.7A). We seeded human fetal astrocytes to the underside and HBMEC to the 
top side of 3.0 um PET membrane inserts to model the interaction of astrocytes and endothelial 
cells at the BBB. With the monolayer established, we added purified human monocytes to the upper 
chamber and CCL2 to the lower chamber (Fig. 3.1B). After 24h of incubation, we observed a robust 
increase in monocyte migration to the lower chamber in preparations with CCL2 in the lower 
chamber (Fig. 3.7B-C). However, we observed no differences in permeability to 70kDa FITC-
dextran post-migration in any condition (Fig. 3.7D), suggesting that i) CCL2 did not disrupt the 
HBMEC monolayer and ii) monocytes migrated through diapedesis along the chemotactic gradient. 
 
3.5 Discussion 
Based on our prior work suggesting HO-1 loss as a risk for HIV NCI and literature describing the 
protective effect of HO-1 in endothelial cell function, we sought to determine the role for endothelial 
HO-1 expression in BBB functions in HIV infection. We evaluated the feasibility of specifically 
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manipulating HO-1 expression and modeling BBB functions in two in vitro brain endothelial models: 
the hCMEC/D3 cell line and primary human brain microvascular endothelial cells (HBMECs).  
 
Both hCMEC/D3 cells and HBMECs demonstrated robust induction of HO-1 expression when 
exposed to CoPP, confirming that while basal endothelial HO-1 expression is low, its inducibility is 
similar to what we have observed in monocyte-derived macrophages (36). In hCMEC/D3 cells, we 
also observed increased HO-1 expression with ARE inducers DMF and MMF, as well as IFNβ. 
These data are relevant to future in vitro and in vivo experiments targeted toward exploring HO-1 
inducers as adjunctive therapy in HIV infection; each is FDA-approved for treatment of multiple 
sclerosis (243-245). HO-1 induction by DMF and MMF through transcription factor Nrf2 is well-
established in other cell types, including monocyte-derived macrophages and astrocytes (167, 246-
248). Our results are consistent with data from Lim et al. showing HO-1 induction in response to 
MMF that was accompanied by decreased expression of adhesion molecules and transendothelial 
monocyte migration (216). We speculate that exposure of hCMEC/D3 cells to DMF and MMF would 
similarly limit transendothelial migration of HIV-infected CD4+ T cells.  
 
IFNβ also supports BBB function by limiting adhesion molecule expression and tight junction 
destabilization in response to pro-inflammatory stimuli (240). The role for HO-1 in IFNβ-mediated 
BBB function has been explored in the context of multiple sclerosis, with conflicting results. HO-1 
expression in the CNS is increased in multiple sclerosis, but whether this is protective or pathologic 
is unclear. In one study, PBMCs from patients with exacerbated disease had decreased HO-1 
expression, and IFNβ administration surprisingly correlated with HO-1 reduction. However, here, 
we demonstrate modest induction of HO-1 expression in hCMEC/D3 cells with IFNβ exposure. HO-
1 has also been shown to regulate IFNβ production (249, 250), suggesting bi-directionality and 




Specific modulation of HO-1 without off-target effects introduced using pharmacologic or 
immunologic agents is required to define the role for HO-1 in endothelial cell functions. We 
established reliable induction and knockdown of HO-1 expression using siRNA in both hCMEC/D3 
cells and HBMECs. In hCMEC/D3 cells, we were able to apply the Lipofectamine RNAiMax protocol 
that we have previously used successfully in primary human monocyte-derived macrophages and 
primary human fetal astrocytes to knock down HO-1 using siRNA directly targeting HO-1, and to 
induce it by targeting its transcriptional suppressor BACH1 (36, 215) (Kovacsics et al., 
unpublished). Effects of siRNA manipulation of HO-1 expression were long-lasting, over the course 
of several days. These data are a useful tool for future experiments involving HO-1 in hCMEC/D3 
cells.  
 
In HBMECs, however, siRNA delivery was more challenging. In experiments not shown here, we 
attempted to deliver siRNAs to HBMECs using Lipofectamine under many variable conditions: 
increased concentration of siRNA, decreased plating density of cells, alternative plate coating 
materials, and alternative media formulations. None of these adjustments were sufficient to 
facilitate siRNA delivery by Lipofectamine. Gresch and Altrogge described the challenges of 
transfecting primary cells, and detailed efficient transfection of human umbilical vein endothelial 
cells by electroporation instead (251). Similarly, Slanina et al. demonstrated that transfection with 
the Nucleofector II system from Lonza yielded significantly greater transfection efficiency compared 
to Lipofectamine and other similar transfection methods (234). We, too, had success using the 
Amaxa Nucleofector II system, with appreciable knockdown and induction of HO-1 24h post-
transfection in HBMECs. However, in contrast to our results in hCMEC/D3 cells, our data temper 
expectations for future experiments specifically manipulating HO-1 in HBMECs. First, 
electroporation is considerably toxic (approximately 50%). Second, HO-1 knockdown and induction 
did not extend beyond 24h post-transfection (data not shown). Finally, the effects of siRNAs on 
HO-1 expression were more modest than we have observed in hCMEC/D3s and monocyte-derived 
macrophages. Thus, the window of time in which experiments can be done with certainty that HO-
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1 is either induced or knocked down is relatively short, and the quantity of cells available in each 
preparation is limited. Indeed, against our hypothesis, HO-1 manipulation did not impact adhesion 
molecule expression in response to TNFα. We speculate that the modesty of HO-1 knockdown and 
induction by siRNA in HBMECs is the reason for these negative data. For more permanent HO-1 
manipulation in HBMECs that will generate ample cells for experiments, lentiviral transduction 
might be considered. 
 
In addition to manipulating endothelial HO-1 expression, we sought to model key endothelial cell 
functions, including regulation of tight junction permeability and transendothelial migration of 
monocytes. We used an assay measuring endothelial monolayer permeability to 70kDa FITC-
Dextran to evaluate tight junction integrity in both hCMEC/D3 cells and HBMECs. In hCMEC/D3 
cells, we sought to increase monolayer impermeability by exposing cells to pro-inflammatory 
cytokines (TNFα or IFNγ), as others have demonstrated (241). Based on data from Forster et al. 
describing that hydrocortisone inhibits pro-inflammatory effects of TNFα and IFNγ in hCMEC/D3 
cells (242), we eliminated hydrocortisone from the media. Still, exposure to neither TNFα nor IFNγ 
consistently increased hCMEC/D3 cell monolayer permeability in our hands. Similarly, 
manipulation of HO-1 expression did not significantly impact hCMEC/D3 cell monolayer 
permeability. When we combined these techniques and transfected hCMEC/D3 cells prior to 
exposure to TNFα, our results suggested that HO-1 induction may protect against TNFα-induced 
permeability (Figure 3). However, these data are difficult to interpret because exposure to TNFα 
did not consistently increase hCMEC/D3 cell monolayer permeability, suggesting that this model 
may not recapitulate in vivo barrier properties that had been previously reported	(241). Ultimately, 
these data led us to use this permeability assay to confirm monolayer integrity as opposed to as a 
functional readout.  
 
Finally, and perhaps most importantly, we sought to model transendothelial migration of monocytes 
in both hCMEC/D3 cells and in HBMECs in co-culture with primary human fetal astrocytes. In each, 
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we successfully modeled enhanced monocyte transmigration in response to CCL2, as has been 
previously demonstrated (237). Due to the efficiency of siRNA transfection achievable in 
hCMEC/D3 cells, this model would be ideal for determining the role for endothelial HO-1 in 
modulating transendothelial migration of monocytes. The HBMEC co-culture model, on the other 
hand, would be ideal for determining the role of astrocytic HO-1 in this context, as we have 
previously demonstrated efficient siRNA transfection via Lipofectamine in primary human fetal 
astrocytes (Kovacsics et al., unpublished). We also demonstrated increased adhesion molecule 
expression in response to TNFα and IFNγ in HBMECs. Given these data, we expect that exposure 
to TNFα and IFNγ would enhance transendothelial migration of monocytes and potentially CD4+ T 
cells in each model (252). These proof-of concept experiments pave the way for future studies 






Figure 3.1 Functional modeling of the blood-brain barrier using a transwell system 
 (A) Schematic illustrating processes used to evaluate blood-brain barrier functions in hCMEC/D3 
cells. (B) Schematic illustrating processes used to evaluate blood-brain barrier functions in tri-

























































Figure 3.2 HO-1 responds predictably to pharmacologic manipulation in hCMEC/D3 cells 
(A) Representative Western blot of hCMEC/D3 cell lysates collected 24h after exposure to 10uM 
CoPP. (B) HO-1 expression was determined by densitometry analysis normalized to GAPDH (n=2). 

























































































































































MMF for 0h, 4h, 8h, 24h, or 48h. (D) HO-1 expression was determined by densitometry analysis 
normalized to GAPDH (n=3). (E) Representative Western blot of hCMEC/D3 exposed to 0.1ng/mL, 
0.5ng/mL, or 1ng/mL IFNβ for 1, 4, or 6 days. (F) HO-1 expression was determined by densitometry 
analysis normalized to GAPDH (n=2). Statistical comparisons to untreated were made by 2-way 






Figure 3.3 hCMEC/D3 cell blood-brain barrier model recapitulates cytokine-induced 
monocyte chemotaxis, but not barrier permeability 
(A) hCMEC/D3 cells were seeded onto 0.4um-pore PET inserts and permeability was determined 
2, 4, 6, or 8 days after plating (n=1-2). (B) hCMEC/D3 cells were seeded onto 0.4um- or 3.0um-
pore PET inserts and transferred to either serum-free endothelial cell media or RPMI with 5% FBS 













































































































































































CCL2 - Upper & Lower 
Chambers
































CCL2 - Lower Chamber






Holm-Sidak post hoc test for multiple comparisons (n=2). (C) hCMEC/D3 cells seeded to 0.4um-
pore PET inserts in ECM media with or without hydrocortisone were exposed to 5ng/mL or 10ng/mL 
TNFα for 24h prior to permeability assay. (D) hCMEC/D3 cells seeded to 0.4um-pore PET inserts 
in ECM media with and without hydrocortisone were exposed to 5ng/mL or 10ng/mL IFNγ for 24h 
prior to permeability assay. (E) hCMEC/D3 cells seeded to 0.4um-pore PET inserts in ECM media 
with and without hydrocortisone were exposed to vehicle (0.1% BSA) or 200ng/mL CCL2 24h prior 
to permeability assay. (C, D, E) Statistical comparisons in each culture condition to untreated were 
made by one-way ANOVA with Holm-Sidak post-hoc test for multiple comparisons (n=2-4). (F) 
Vehicle (0.1% BSA) or 200ng/mL CCL2 were added concurrently with monocytes to the indicated 
chambers. Monocytes in the lower chamber were counted after 20h, 24h, or 48h. Statistical 
comparisons to vehicle at each time point were made by one-way ANOVA with Holm-Sidak post-





Figure 3.4 Genetic manipulation of HO-1 may prevent inflammation-induced permeability in 
hCMEC/D3 cells 
(A) Representative Western blot of hCMEC/D3 cell lysates collected 24-96h after transfection with 
siRNA targeting HO-1 or BACH1. (B) Permeability assay was performed 72h post-transfection. 
Statistical comparisons to scramble were made by one-way ANOVA with Holm-Sidak post-hoc test 
for multiple comparisons (n=2). (C) 48h after siRNA transfection, hCMEC/D3 cells were exposed 
to 10ng/mL TNFα for 24h, followed by permeability assay. Statistical comparisons to untreated 
were made by two-way ANOVA with Holm-Sidak post-hoc test for multiple comparisons (n=2). 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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Figure 3.5 Primary human brain microvascular endothelial cells express HO-1 in response 
to pharmacologic and genetic manipulation 
(A) Representative Western blot of HBMEC lysates collected 24h after exposure to 10uM CoPP. 
(B) Quantification of Western blot of HBMECs treated with 100nM, 1uM, or 10uM CoPP for 0h-48h. 
HO-1 expression was determined by densitometry analysis normalized to GAPDH. Statistical 
comparisons to untreated were made by 2-way ANOVA with Holm-Sidak post-hoc test for multiple 
comparisons, n=2. (C) Representative Western blot of HBMEC lysates collected 24h after 
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Figure 3.6 Pro-inflammatory cytokines increase endothelial adhesion molecule expression 
in HBMECs 
 (A) Representative Western blot of HMBEC lysates collected 24h after exposure to 0.5-20ng/mL 
TNFα or (B) IFNγ. (C-D) ICAM-1 and VCAM-1 expression were determined by densitometry 
analysis normalized to b-tubulin. Statistical comparisons to untreated were made by repeated 
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measures two-way ANOVA with Holm-Sidak post-hoc test for multiple comparisons (n=2). (E) 
Representative Western blot HBMEC lysates collected 24h after electroporation with siRNA 
targeting HO-1 or BACH1, followed by 24h exposure to 1 or 10ng/mL TNFα. (F) ICAM-1 and (G) 
VCAM-1 expression were measured by densitometry analysis normalized to GAPDH. Statistical 
comparisons to untreated were made by mixed-effects analysis with Holm-Sidak post-hoc test for 






Figure 3.7 HBMEC tri-culture blood-brain barrier model recapitulates cytokine-induced 
transendothelial migration of monocytes 
 (A) Phase-contrast images of HBMECs and human fetal astrocytes (HFAs). (B) Monocyte 
transmigration assay was performed as described in Fig. 3.1B with 100-400ng/mL CCL2 in the 
lower chamber throughout the 24h migration period. (D) Phase-contrast images of representative 
10x fields from each of the conditions in (C). (E) Permeability of HBMEC-HFA monolayers was 
determined after the transmigration period. Statistical comparisons to untreated were made by one-
way ANOVA with Holm-Sidak post-hoc test for multiple comparisons (n=3). *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
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The introduction of combination antiretroviral therapy (cART) has profoundly altered the prognosis 
associated with HIV infection, extending the life expectancy for persons living with HIV (PLWH) to 
nearly as long as that of HIV-negative population (1). Still, PLWH experience significant 
comorbidities to HIV infection, including HIV NCI, which associates with persistent inflammation 
and oxidative stress. In previous work, we have defined a novel role for antioxidant enzyme HO-1 
in the pathogenesis of HIV NCI by identifying its deficiency in prefrontal cortex of individuals with 
HIV NCI. Building upon this study, we analyzed the distribution of genotypes for the (GT)n 
dinucleotide repeat polymorphism in PLWH stratified by CNS disease parameters. We found that 
shorter repeat length alleles associated with decreased risk for both HIV-encephalitis and HIV NCI 
(36, 114, 115). Short repeat length alleles associate with higher basal expression and inducibility 
of HO-1 in multiple cell types (90, 91). Together, these data suggest that individuals with shorter 
repeat length alleles, through relatively greater HO-1 expression and induction, have a greater 
antioxidant capacity that benefits disease outcomes including HIV NCI. These ex vivo findings are 
supported by in vitro studies demonstrating supernatant neurotoxicity of HIV-infected monocyte-
derived macrophage associated with HO-1 deficiency, as well as post-translational degradation of 
HO-1 by the immunoproteasome in astrocytes chronically exposed to HIV-associated inflammatory 
cytokine IFNg (36, 104). In the current work, we sought to develop our understanding of the role for 
HO-1 in HIV NCI in several areas not yet fully addressed: i) whether the HO-1 response to HIV 
infection is consistent throughout the brain; ii) how HO-1 expression relates to neuroinflammation 
in PLWH without HIV NCI; and iii) how HO-1 expression impacts brain microvascular endothelial 
cell (BMEC) and blood-brain barrier (BBB) functions in the context of HIV infection. 
 
In the study described in Chapter 2, we established that HO-1 protein expression is stable or 
increased throughout the brain in PLWH without HIV NCI. This result is consistent with our previous 
study in prefrontal cortex, which found that prefrontal cortex HO-1 protein in PLWH without HIV 
NCI was not significantly different from HIV-negative individuals, but was significantly higher than 
in PLWH with HIV NCI (36). The reasons why HO-1 expression is higher in PLWH without HIV NCI 
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than in those with HIV NCI are unclear, although our prior studies suggest that the loss of HO-1 
may be explained by immunoproteasome-mediated degradation in a subset of PLWH. We and 
others have reported elevated immunoproteasome expression and interferon responses in brains 
of PLWH irrespective of the concurrent diagnosis of HIV NCI (46, 105, 253). However, our 
subsequent study showed those with HIV NCI, HO-1 protein was low and this suggested that IFN-
driven immunoproteasome expression enhances degradation of HO-1 protein in those individuals 
who develop HIV NCI, accounting for the discordance observed between brain HO-1 protein and 
RNA in those individuals (104). In this current study of PLWH without HIV NCI, we observed a 
positive association between brain HO-1 protein and RNA expression, despite elevated type I IFN-
stimulated gene and immunoproteasome expression. The lower HO-1 protein expression in those 
with HIV NCI may reflect a threshold of immunoproteasome induction required for HO-1 
degradation that is achieved only in PLWH who develop HIV NCI. Nonetheless, it is possible that 
mechanisms involved in HO-1 loss are triggered by duration of HIV infection or other unidentified, 
independent factors. Our data identified distinct regional patterns of neuroinflammation in brains of 
PLWH without HIV NCI. Posterior cingulate cortex, cerebellum, and globus pallidus each had 
higher immunoproteasome subunit and interferon-stimulated gene expression in PLWH compared 
to HIV-negative individuals. We believe that these data indicate a proclivity towards HIV-induced 
neuroinflammation in these regions, and HIV-induced abnormalities have been identified by others 
in each (147, 186, 198, 204). 
 
PLWH in this cohort did not have HIV NCI, nor did any of these regions have altered expression of 
synaptic markers. However, there still may be functional consequences to such changes. In a 
preliminary analysis following up this study, we observed an association between poorer executive 






Figure 4.1 Higher IFN-stimulated gene MX1 expression in posterior cingulate cortex 
associates with poorer executive function in PLWH 
Neurocognitive evaluation to determine assess performance in domains including executive functioning was 
performed by a neuropsychologist approximately 6 months before death. Test results were transformed to 
age-education-corrected scores (T scores) (254). MX1 RNA expression was measured by RT-qPCR.  
Associations between MX1 RNA expression and executive domain test T score were analyzed by Pearson’s 
correlation with line of best fit by linear regression. 
 
We recognize that the current cohort is underpowered to draw definitive conclusions from 
associations such as this. Prospective neuroimaging (MRS, PET) studies are more appropriate 
than post-mortem studies for analyses associating inflammatory biomarkers with 
neuropsychological testing performance, especially in the case of HIV NCI wherein the 
neurocognitive trajectory is not typically progressive (122). Longitudinal studies in which 
neuroimaging data collection and neuropsychological evaluation are temporally matched can more 
accurately define how potentially fluctuating local neuroinflammation can impact cognition (255). 
Nonetheless, our data are consistent with another report describing inflammation in the PCC that 
associates with poorer executive function in PLWH (147). 
 
In this study, we also sought to determine the significance of brain regional variation of HO-1 
expression in PLWH. Given the evidence for differential regional expression of HO-1 in the human 
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brain (164), we hypothesized that regions expressing lower HO-1 would be more vulnerable to HIV-
mediated inflammation or neuronal damage. While we did observe statistically significant variation 
of HO-1 expression by brain region, regions with distinct neuroinflammation (posterior cingulate 
cortex, globus pallidus, and cerebellum) did not have consistently higher or lower HO-1 expression 
levels relative to the rest of the brain. These results do not necessarily rule out our original 
hypothesis. We previously showed that PLWH with HIV encephalitis have reduced HO-1 
expression in the striatum (caudate) in addition to prefrontal cortex, but not the occipital cortex or 
cerebellum, suggesting that HIV NCI-associated HO-1 deficiency is regionally specific (36). 
However, these regions were not compared to one another, so their relative expression of HO-1 is 
unknown. It is possible that in PLWH with HIV NCI and deficient HO-1, those regions with lower 
HO-1 expression are more vulnerable to HIV-mediated inflammation and injury due to an 
insufficient antioxidant response. A future study including matched groups of HIV-negative 
individuals, PLWH without HIV NCI, and PLWH with confirmed HIV NCI in key brain regions 
identified here would more clearly define i) implications of regional differences in HO-1 expression 
in PLWH with and without HIV NCI; and ii) how HO-1 expression compares between PLWH with 
and without HIV NCI in each region. 
 
The consequences of altered brain HO-1 expression in PLWH remain to be determined, and 
important relationships are suggested. We previously linked low HO-1 expression in the brain to 
HIV NCI, and low HO-1 expression in human macrophages to neurotoxin production, which could 
result in neuronal injury and dysfunction (36, 166). In this work, we extended observations to 
demonstrate increased expression of endothelial adhesion molecules (ICAM-1, PECAM-1, and 
VCAM-1) in PLWH and without HIV NCI compared to HIV-negative individuals, and associations 
with HO-1 expression. We speculate that this increase of endothelial adhesion molecules promotes 
increased adhesion and migration of immune cells through the blood-brain barrier, which could 
promote local inflammation. The clustering of ICAM-1 and VCAM-1 at the apical surface of 
endothelial cells and facilitation of leukocyte adhesion prior to diapedesis is well known (207). 
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Increased expression of ICAM-1 precedes transendothelial migration in ischemic stroke (209), and 
the duration and intensity of ICAM-1 expression not only promotes migration but also mediates the 
route of migration (210). Similarly, VCAM-1 is upregulated and facilitates migration of antigen-
presenting cells into the CNS during viral infection (211).  However, although PECAM-1 expression 
is not consistently increased during inflammation, its localization to tight junctions is, and this 
supports transendothelial diapedesis of cells (256).  
 
Notably, our data indicate that HO-1 expression also associates positively with endothelial cell 
adhesion molecule expression in HIV-infected brain, and this suggests functional consequences. 
We suspect that this positive association, along with the higher levels of endothelial cell adhesion 
molecules in PLWH compared to HIV-negative individuals, represents the independent induction 
of each by HIV infection, but modulating effects of HO-1 on endothelial cell adhesion molecule 
expression are possible. Among endothelial cell functions, transendothelial immune cell adhesion 
and migration can be modulated by HO-1; HO-1 induction decreases monocyte transmigration in 
response to oxidized LDL in human aortic endothelial cells (257) and HO-1 induction in human 
umbilical vein endothelial cells before exposure to IFNγ reduces T-cell adhesion	(258). Astrocytic 
HO-1 expression may mediate endothelial cell function through secreted factors (259). Additional 
in vitro analyses are required to model and define mechanisms by which HO-1 expression might 
also modulate endothelial cell function in HIV-infected brain.  
 
We have shown that HO-1 protein expression throughout the brain in PLWH without NCI is 
comparable to or higher than that in HIV-negative individuals, in contrast to lower brain HO-1 
protein levels in PLWH with NCI observed in our prior studies. This finding, coupled with our 
previous in vitro and in vivo studies demonstrating a strong protective effect of HO-1 on HIV-
associated neuronal injury, neuroinflammation, and neurocognitive impairment suggest that 
maintaining, or even increasing, brain HO-1 expression in PLWH may delay or even prevent the 
development of these HIV-associated pathologies. We speculate that targeting the transcriptional 
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regulation of HO-1 or post-translational degradation of HO-1 offer therapeutic opportunities for 
neuroprotection against HIV. 
 
One useful class of HO-1-inducing drugs that penetrate into the CNS is the class of fumaric acid 
esters, namely dimethyl fumarate (DMF) and its primary in vivo metabolite monomethyl fumarate 
(MMF). Oral DMF, formulated as the FDA-approved drug, Tecfidera, is now commonly used for 
effective treatment of multiple sclerosis, a disease characterized by neuroinflammation and 
oxidative stress (260, 261). Just this year, oral MMF has also been FDA-approved for multiple 
sclerosis treatment in the United States, under the proprietary name Bafiertam (262, 263). DMF 
and MMF induce HO-1 expression through activation of the Nrf2-dependent antioxidant response 
as well as inhibition of NF-kB signaling (reviewed in (264)). We have confirmed that DMF and MMF 
each induce HO-1 in HIV-infected human macrophages (36, 167) and human brain microvascular 
endothelial cells (HBMECs) (Chapter 3). Pre-treatment of HIV-infected macrophages with DMF or 
MMF significantly inhibits HIV infection and reduces neurotoxin production (167). Furthermore, 
DMF and MMF treatment of HIV-infected macrophages after HIV infection is established does not 
alter HIV replication, but does significantly reduce glutamate release and associated neurotoxicity, 
similar to other HO-1 inducing strategies	(167). Additionally, DMF and MMF inhibit macrophage 
NF-κB nuclear translocation, decrease TNFα release, and reduce CCL2-mediated monocyte 
translocation (265), each of which could limit macrophage-mediated neuroinflammation in ART-
treated individuals. Whether DMF and MMF support BBB function in vivo is controversial. Exposure 
of HBMECs to DMF in vitro supports tight junction integrity, and exposure of activated HBMECs to 
MMF reduced expression of VCAM-1 transendothelial migration of monocytes (266, 267). 
However, another in vitro study found that neither DMF nor MMF altered adhesion molecule 
expression or T cell adhesion to HBMECs (268). Furthermore, DMF treatment had no effect on 
structural tight junction protein claudin-5 expression in experimental autoimmune 
encephalomyelitis (EAE), a commonly used animal model for multiple sclerosis (269). Still, 
considerable evidence supports the study of HO-1 inducers such as DMF as adjunctive therapy in 
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ART-treated HIV-infected subjects to limit neuroinflammation, oxidative stress, blood-brain barrier 
disruption, and associated neurocognitive impairment. In a study in progress, we have treated 
rhesus macaques with DMF prior to infection with simian immunodeficiency virus (SIV). DMF-
treated macaques had higher expression of Nrf2 antioxidant response element genes, including 
NQO1, GPX1, and a clear trend towards increased HO-1 expression although this was not 
statistically significant. Confirmation of induction of antioxidant response element genes in the brain 
to DMF within this model warrants further study.  
 
Another candidate drug of interest for HO-1 induction is bardoxolone-methyl, a semi-synthetic 
triterpenoid that has been investigated for treatment of chronic kidney disease and some cancers. 
Similar to DMF and MMF, bardoxolone-methyl induces antioxidant response element proteins 
through activation of the Keap1/Nrf2 pathway and inhibition of NFκB nuclear translocation (270). 
Bardoxolone-methyl has also demonstrated antiviral effects, limiting replication of hepatitis B and 
C in vitro (271). In a model of ischemia reperfusion injury, treatment with bardoxolone-methyl 
decreased infarction volume and improved neurological symptoms after injury (272). Further study 
found that the protective effects of bardoxolone-methyl in this model were mediated in part by 
preventing BBB disruption, specifically through maintenance of tight junction molecule expression 
(273). In preliminary studies, we found that treatment of monocyte-derived macrophages with 
bardoxolone-methyl prior to HIV infection suppressed viral replication and limited supernatant 
neurotoxicity of HIV-exposed monocyte-derived macrophages. Further study of bardoxolone-
methyl within HIV-infected monocyte derived macrophages and BBB models are required to 
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